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ABSTRACT 
Tumors p roduce mu ltiple angiogenic f actors to  s timulate n eovascularization th at is 
essential f or t umor growth, i nvasion and m etastasis.  D espite t he know n a ngiogenic 
functions of each individual factor, the interplay between these angiogenic factors in the 
tumor l ocal e nvironment a nd i n m odulation of  t he host functions remain poo rly 
understood.  T his thesis addresses these important and complex issues using various in 
vitro a nd i n vi vo experimental m odels.  The findings f rom t hese s tudies pr ovide 
mechanistic insights on the  of complex interplay between various angiogenic factors and 
on the systemic impact of these tumor-derived factors on the host.  In paper I, we showed 
one of the first examples of two unrelated angiogenic factors, i.e., FGF-2 and PDGF-BB 
that r eciprocally modulate t umor a ngiogenesis an d m etastasis.  W e found t hat FGF-2 
markedly u pregulates t he ex pression l evels o f P DGFRα and β in e ndothelial c ells, 
leading t o t he h ypersensitive r esponse o f t hese cel ls t oward P DGF-BB stimulation.  
Reciprocally, P DGF-BB is a lso a ble t o upr egulate t he e xpression l evel of  F GFR-1 i n 
perivascular cells.  T he angiogenic s ynergism an d v ascular remodeling b y these t wo 
factors markedly accelerates tumor growth rates, leading to an invasive phenotype in a  
mouse xenograft tumor model.  In paper II, we describe a negative interplay between two 
angiogenic factors that significantly modulate the number and structure of tumor blood 
vessels.  P lGF c ould negatively modulate V EGF f unctions b y the formation o f 
heterodimers d uring th eir s ynthesis in  th e s ame cell.  W e s how th at th e PlGF-VEGF 
heterodimers a re less pot ent than VEGF homodimers and thus significantly r educe the 
angiogenic a ctivity o f V EGF.  S urprisingly, w e found t hat m odulation o f t he V EGF-
induced angiogenic activity by PlGF markedly normalize tumor vessels.  P lGF-induced 
vascular n ormalization may imp ly increased therapeutic ef ficacy o f an tiangiogenic 
drugs.  In paper III, we showed that tumor-derived VEGF and PlGF can enter into the 
circulation and systemically impair vascular functions of other tissue and organs.  In this 
paper, we proposed a new mechanism of cancer-associated retinopathy caused by tumor-
derived angiogenic f actors.  U nlike vasculatures distributed in other t issues, the r etinal 
vasculature predominantly expresses VEGFR1, but lacks a detectable level of VEGFR2.  
Tumor-derived V EGF and P lGF s ignificantly a blate vascular p ericytes, l eading t o 
increased l eakiness o f t he r etinal v asculature.  T hese f indings s uggest t hat t argeting 
tumor-derived VEGF, P lGF or o ther r elated angiogenic f actors m ight provide a n ew 
therapeutic strategy for the treatment of cancer-associated retinopathy, which otherwise 
remains u ntreatable.  In p aper IV, w e d iscovered a n ew m echanism u nderlying t he 
combination t herapy b etween a ntiangiogenic d rugs and chemotherapeutics.  B ased on 
preclinical f indings, we pr opose that d ecreased chemotoxicity b y antiangiogenic d rugs 
might significantly contribute to survival advantages of patient receiving a combination 
of these two classes of drugs. We have also rationalized the optimal delivery of these two 
drugs by using a sequential procedure rather than a simultaneous schedule as currently 
recommended in clinical settings.  Taken together, this thesis work reveals several novel 
mechanisms of tumor a ngiogenesis a nd provides nove l information of  a ntiangiogenic 
therapy, which can be further optimized based on the work reported in this thesis.  This 
thesis w ork r epresents t ranslational and that me chanistic s tudies which can l ead t o 
clinically meaningful implications and our eventual goal is to improve survival and the 
quality of life for millions of cancer patients. 
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1 INTRODUCTION 
 
1.1 ANGIOGENESIS, A HISTORICAL VIEW 
In the early 1970s Dr Judah Folkman (Harvard Medical School, USA) proposed that 
a solid tumor of 2-3 mm in size is in need of neovascularization, to transform from a 
dormant t o g rowing t umor [1]. T oday i t i s know n t hat m aximum s ize f or dor mant 
tumors is e ven de creased t o 1 m m. T his pr ocess of  ne ovascularization, or  r ather 
angiogenesis, was not new knowledge, but it was not until now that the importance of 
tumor a ngiogenesis w as hi ghlighted. A lready i n t he l ate 17 th century a S cottish 
surgeon, D r J ohn Hunter, a nd s cientist s tudied t he a natomy o f t he va sculature a nd 
revealed vol uminous s everal f acts, i ncluding t hat t he m aternal a nd f etal bl ood i s 
separated, the anatomy of the lymphatic system which was a puzzle at the time, and 
he described for the first time angiogenesis, revealed after reindeers were exposed to 
cold [2]. A lthough i t w as not  unt il 1935 t he t erm a ngiogenesis w as u sed i n t he 
description of  ne ovascularization i n t he pl acenta b y Dr Arthur T  Hertig [3]. 
Angiogenesis or iginates f rom t he G reek word angêion meaning v ase and genesis 
meaning birth.  
 
1.2 THE PROCESS OF ANGIOGENESIS 
Angiogenesis i s a  p rocess w here ne w ve ssels s prout f rom a n e xisting vessel. T he 
stimulated endothelial cells (ECs) produce proteases to degrade the nearby basement 
membrane. The ECs will then s tart to  p roliferate, d ifferentiate and mi grate in to the 
tissue, forming a new vessel. Growth factors, produced by the thin layer of ECs, will 
be released and attract mural cells; smooth muscle cells (SMCs) and pericytes, to line 
the vessels for stability and support  [4]. 
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More s pecifically, one  of  t he E Cs e xpressing Vascular E ndothelial G rowth F actor  
Receptor 2  ( VEGFR2) will d ifferentiate in to a  s o-called tip  c ell w ith e xtensive 
filopodia pr otrusions i n t he pr esence of  a c hemoattractant s uch a s t he a ngiogenic 
factor; V ascular E ndothelial G rowth Factor-A ( VEGF-A). T his m olecule can  b e 
either e xpressed b y, for a n e xample t umor c ells, or  be  upr egulated a lso i n non -
malignant cells due to a hypoxic environment. The tip cell will be the leading cell of 
the s prout o f th e v essel, a nd th e tip  c ell w ill migrate in  in  th e d irection of  t he 
attractants. The tip cell will not form a lumen, to shape a new vessel, but this role is 
rather performed by the cells trailing along, called stalk cells. These stalk ECs, which 
do not  f orm t he f ilopodias, pr oliferate and f orming a  s talk c ontaining a  l umen, 
connected to the pre-existing vessel and thereby extending the blood circulation. The 
stalk E C phe notype i s i nduced b y a ctivation of  t he N otch1 r eceptor b y D elta l ike 
ligand 4 ( Dll4) a nd e xpressed on ne ighboring t ip c ell, w hich l eads t o a  dow n 
regulation o f V EGFR2 in  th e s talk c ells [5, 6]. The s talk c ells a ttract m ural c ells; 
small cap illaries will be covered b y pericytes and l arger vessels will be covered b y 
SMCs. T he pe ricytes w ill s uppress m igration a nd pr oliferation of  t he ECs, a nd 
support t he s tability o f t he ve ssels i n a  V EGF-A-dependent m anner [6, 7]. 
Furthermore, v ascular a blation o f p ericytes will le ad to  d ecreased s tability a nd 
increased vessel permeability or leakage.  
Another well characterized angiogenic factor involved in the vascular development is 
Platelet-Derived G rowth F actor-BB ( PDGF-BB) a nd i ts r eceptor β (PDGFR β) [8]. 
PGDF-BB i s know n t o be a  S MC m igratory factor [9], but  t he i mportance of  t his 
factor in  E C mi gration i s mo re s peculative a s m ost ma ture E Cs in  h ealthy tis sues 
seems not to express the receptor [8].   
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1.3 VASCULAR PERMEABILITY 
Depending on w ho r ead t he w ords va scular p ermeability, i t w ill ha ve di fferent 
meanings. For the physiologist the interest of permeability is generally of the passive 
barrier constituted by the ECs, as a m embrane-like filter, where small molecules can 
pass through freely, e.g. O2 and CO2 and where a limited number of plasma proteins 
pass t hrough l arge por es. T he physiologist often us es calculations of  di fferent 
perfusion pa rameters t o evaluate t he pe rfusion v alue. T he v ascular bi ologist on t he 
other hand, preferably studies the vessel permeability in the term of the properties of 
the vessels. These properties include the blood flow or the visible extravasation. For 
example, t he m ice g et a n i njection o f a d ye, an d t he t issue o f i nterest i s an alyzed; 
using the dye as a perfusion value.  
VEGF-A is  the most well known permeability factor, and can cause immediate but 
limiting hyper-permeability of healthy vessels, and also chronic hyperpermeability in 
disease, such as rheumatoid arthritis, wound healings, or in tumors [10]. VEGF-A can 
cause EC fenestrations, pore-like openings, though the Calcium activation [11]. These 
EC f enestrae allow r apid m olecular ex change between t he t issue an d t he b lood 
circulation, a nd t he f enestrations a re p resent o f the s inusoidal ve ssels i n l ymphoid 
tissue, endocrine organs, hematopoietic organs, and the placenta villi. Recently it has 
been s hown t hat i n the P DGF-mediated an giogenesis, V EGF-A is  c ausing p ericyte 
loss an d t hereby i mmature v essels. V EGF-A ac tivates VEGR2, w hich will in hibit 
PDGFRβ by forming a  complex with it  [12]. For more description of  t he VEGF-A 
expression in fenestrated tissue, see the section of VEGF. 
 
Why v ascular p ermeability is  s o in teresting in  tumors, i s not  j ust l eakiness of  t he 
vessel. But rather,  i t is possible for the tumor cells to enter the blood vessel, follow 
the blood stream and stop by a location, where it p ossibility starts to proliferate and 
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cause a new secondary tumor, a metastasis, which has high possibility of being lethal 
for t he pa tients [13] (figure 1). T his ha s be en seen i n pa tients. In a s tudy of  92  
surgically removed tumors of colorectal cancer, the higher tumor vessels density and 
lesser SMCs coverage were strongly correlated with metastasis and poorer prognosis 
[14]. 
 
 
Figure 1. Healthy and tumor vessels (modified from [15]). 
 
1.4 TUMOR ANGIOGENESIS AND METASTASIS 
Tumor a ngiogenesis i s r eferred t o w hen t he t umor r eleases a  m ultitude of  g rowth 
factors, E CM br eaking signals, cytokines, a nd etc, w hich s timulate th e g rowth o f 
blood ve ssels i nto t he t umor. T he n earby t issues o r m ore s pecifically the n earby 
vascular cells, will respond to some or several of these factors. If the tumor appears in 
the area of a nearby vessel, this increases the risk of progressive tumor growth due to 
tumor angiogenesis. W ithout t he bl ood ve ssel t he s olid t umor w ill m ost likely s tay 
dormant [1]. The vessels of the healthy tissue stay quiescent due to the dominance of 
angiogenic inhibitors over the stimulators. In the tumor tissue, this is usually not the 
case, du e t o t he ove rproduction of  a ngiogenic f actors. T he t umor grows due t o t he 
increased blood s upply, a lthough t he t umor v asculature be comes i mpaired a nd 
thereby h ypoxic. The h ypoxia cau ses an  u p-regulation of  V EGF-A b y t he hypoxia 
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inducible factor-1 (HIF-1) [16]. This leads to further angiogenesis and the VEGF-A 
induced ve ssels a re s everely di sorganized, tortured, f ull of  va scular pl exuses, 
irregular di ameters, a nd e xcessive br anches. T he bl ood f low is irregular w ith h igh 
interstitial f luid p ressure ( IFP), the v essels are highly p ermeable, an d a re causing 
hypertension [15]. T hese v essels generally l ack m ural cel l co verage, w hich ar e 
important f or t he s tability. T hrough t hese ve ssels i t i s pos sible f or small sub-
populations of  t umor cells t o ‘ escape’. T hey can m igrate t hrough t he bl ood 
vasculature a nd colonize a new t issue, an d cause a m etastasis. T he E Cs l ining t he 
tumor v asculature h ave an  i rregular s hape (not s een i n h ealthy t issue), ar e 
disorganized, and sometimes the EC lie on t op of each other, causing large holes in 
the v essels [17]. H ighly a ggressive t umor cells can also f orm a  t ubular s tructure, 
without the presence of ECs connecting to the blood vessels. This is called vascular-
mimicry [18]. Thereby the t umor has found another w ay to enter the b lood s ystem 
and s pread. A nother w ay for t he t umor t o m etastasize i s t hrough t he s o c alled 
epithelial-mesenchymal transition (EMT). The tumor cells in the invasive frontline of 
the pr ogressing a nd growing t umor c onvert i nto a  m esenchymal phe notype. This 
switches the cells to a more migratory phenotype ad enables them to enter the blood 
stream and metastasize in other places. Once settled in a d ifferent place they convert 
back to epithelial state of the primary tumors [19].  
 
1.4.1 Vessel normalization 
Cancer t reatments can  generally be di vided i nto two g roups, as di scussed i n m ore 
detail later in the therapy section. First and pre-dominantly are the chemotherapeutic 
drugs which kill the tumor cells. The second group is targeting the tumor vasculature. 
Administration o f a nti-angiogenic d rugs w ill disrupt t he t umor va sculature a nd 
thereby the nutrient and oxygen supply [15].  
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Yet, t here i s an alternative t heory. To nor malize t he t umor v asculature b y anti-
angiogenic dr ugs, t hrough inhibition of  t he pro-angiogenic s ignals. T his cau ses 
vessels t o b ecome functional. T he phe notype of a normalized tumor vasculature 
consists of  straight v essels, of  a n e ven di ameter, w hich a re r elatively l ong, and 
therefore look s imilar to  those seen in  healthy (normal) t issue. As described above, 
the IFP is high in the tumor and this is preventing the therapeutic drugs to enter the 
tumor. Thereby the drugs are primarily circulating in the non-tumor vascular system 
causing side-effects, without causing any damage of the actual tumor. By normalizing 
the tumor vasculature, the IFP will decrease, allowing efficiently drug delivery to the 
tumor, thereby maximizing the therapeutic efficiency of these agents the tumor tissue. 
Another reason to normalize the tumor vasculature would be to prevent or  decrease 
the metastatic feature to the tumor, via the blood circulation [13, 15]. 
 
1.4.2 Tumor microenvironment 
Already mentioned is the tumor, and in this thesis I will exclusively refer to tumors of 
the s olid ki nd. I n s olid t umors t he t umor m icroenvironment c onsists of  t he t umor 
cells, which is a cell that has undergone a genetic or epigenetic change. This change 
has led to the malfunctioning of the control machinery such that the cell which should 
undergo apoptosis will not, but rather continue to live and make daughter cells, which 
in their turn might even develop more modification. These modifications, which are 
referred to as the Hallmarks of cancer includes the cells ability to avoid anti-growth 
signals a nd a poptosis, s elf-sufficient in  g rowth signals, p rolonged lif e b y limitless 
replication, sustained angiogenesis and ability to invade other tissues and metastasize 
[20]. The tumor contains more than just tumor cells. A great variety of cells, called 
the s troma; in cluding s tromal c ells, in flammatory cells, e ndothelial c ells, s mooth 
muscle cel ls ( SMC) and p ericytes. T he s tromal c ells c omprise f ibroblasts a nd 
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macrophages, w hereas t he i nflammatory c ells i nclude a n even greater amount of  
cellular c omponents, s uch a s m acrophages, de ndritic c ells, na tural ki ller c ells, a nd 
lymphocytes. [ref]  
The tumor microenvironment produces a multitude of the soluble components. These 
are of  c ourse of  hi gh i mportance, s ince t hese are t he one s w hich i nfluence t he 
surrounding nearby cells, but  a lso can be t ransported through the vessels out to the 
tissues a nd or gans a ll-around t he bod y. These s oluble c omponents, w hich a re 
produces by both the tumor cells but also the stroma, can in fact cause mild but also 
severe systemic syndromes. [ref]  
What m akes up t hese soluble c omponents? T his va ries f rom t umor t o t umor, 
dependent on which original cell caused the tumor, but to generalize the answer; the 
soluble components are cytokines, chemokines, stromal factors, inflammatory factors, 
and angiogenic factors.   
 
1.5 ANGIOGENIC FACTORS 
The an giogenic factors ar e m olecules w ith either o f p ro- or a nti-angiogenic 
properties, s e f igure 2. In a ddition t o t hese m olecules a re ot her f actors, w orth 
mentioning since they influence the tumor vasculature in an un-controlled way during 
the experimental setting, which include hypoxia and mechanical force such as blood 
flow. To concentrate on the vasoactive molecules, which is a continuously increases 
by number, these are usually divided into growth factors and inhibitory factors. 
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Figure 2. Angiogenic growth factors and inhibitors. 
 
1.5.1 Growth factors 
Dependent on t he genetic polymorphism, many different growth factors are released 
by t he t umor, s uch a s angiopoietin, t umor ne crosis f actor ( TNF), a nd t ransforming 
growth factor β (TGFβ). The most potent and well known angiogenic growth factor 
produced by most tumors is the vascular endothelial growth factor (VEGF). Further, 
two ot her w ell know n a nd s tudied, t umor pr oduced a ngiogenic factors a re t he 
fibroblast growth factor (FGF) and platelet derived growth factor (PDGF). 
 
1.5.1.1 Vascular endothelial growth factor (VEGF) 
By the year 1989 a  protein was found by Dr Napoleon Ferrara and coworkers and it 
was named VEGF-A [21], although it was later found that it was the same molecule 
which had been found by Dr Harold Dvorak and coworkers 6 years earlier and at that 
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time it was the molecule had already been named vascular permeability factor (VPF), 
due to  its  ability to  permeabilize the tumor vasculature [22]. The molecule i s of ten 
referred with both names, but more commonly as VEGF-A. 
VEGF c onsist of  a  w hole f amily of  pr oteins. Reading publ ications w ere s imply 
VEGF is  w ritten and not VEGF family, th e authors most likely r efers to  VEGF-A. 
The VEGF superfamily consists of VEGF-A, -B, -C, -D, and PlGF (figure 3). Since 
PlGF is  s o in teresting a nd a  bi t controversial, I w ill de scribe i t l ater i n a  whole 
section. 
 
VEGF-A is known to induce irregular, highly leaky and torturous vessels. Alternative 
splicing of  t he hum an mRNA g ives rise t o s everal di fferent i soforms o f 121, 145, 
165, 183, 189, and 206 amino acid residues. The mouse isoforms are one amino acid 
shorter, r espectively. V EGF-A206 is e xpressed dur ing e mbryonic de velopment, 
whereas the five other isoforms are expressed during adulthood. The smallest isoform 
VEGF-A 121 is a circulating protein, due to its absence of the heparin binding domain, 
which exists in all the other five isoforms, with the larger isoforms having more such 
domains and therefore an increasing affinity for heparin. When heparin interact with 
proteoglycans V EGF-A165, V EGF-A189, a nd V EGF-A206 (although not  V EGF-A145) 
will be deposited into the ECM at a decreasing distance from the producing cell. This 
is causing a chemotactic gradient inducing the ECs to migrate and proliferate towards 
the V EGF-releasing s ite. W ithout th e gradient t he E Cs w ill not  r espond i n s uch a  
highly directional manner. If added alone the 165- isoform causes the most efficient 
gradient and is thereby the most efficient angiogenic inducer. This particular isoform 
is most commonly used in research, including this thesis. 
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Let us  f ocus on V EGF-A, s ince t o our  know ledge up t o da te, V EGF-A i s, a s 
mentioned above, the most potent angiogenic factor [23]. What is the actual function 
in t he bod y? T o s tart w ith t he e mbryonic d evelopment; V EGF-A i s v ital f or 
developmental angiogenesis, a s s een i n t he knoc kout ( KO) m ice w hich are 
embryonically l ethal [24]. D uring e mbryonic d evelopment, e ndothelial pr ogenitor 
cells arising from the mesoderm differentiates in to endothelial cells and produces a 
vascular network. This process is VEGF-A dependent, the endothelial development, 
migration a nd p roliferation is  me diated b y VEGF-A in teraction w ith th e V EGF 
receptor 2  (V EGFR2) [25]; a nd t he t ube formation i s i nduced b y VEGFR1 upon 
VEGF-A binding [26].  
In addition to embryonic development, VEGF-A is indeed al so expressed in almost 
all adult tissues, primarily by in the pericytes and stromal cells. It seems like VEGF-
A have different functions in different tissue, depending on the ratio of expression. In 
tissues where a barrier is needed, such as the blood barrier in the brain, retina, and the 
testis, very few cells express VEGF-A, to limit th e permeability. In the cardiac and 
skeletal muscle tissues, an intermediate VEGF-A expressions is needed for the ability 
of h ypertrophy d ue t o m uscular ex ercise [27]. T he r ichest r atio of  V EGF-A 
expression is in fenestrated vessels, particularly in the epithelia, and special organs: In 
the secreting organs including pancreas, adrenal gland, prostate, and testis. VEGF-A 
is e xpressed i n t he ki dneys of  t he fenestrated glomerulus f or ur ine f iltration. T he 
fenestrations of liver have a VEGF-A expression due to both secretion and filtration 
[28]. 
 
Two i soforms of  V EGF-B ha s be en i dentified b y P rof A litalo a nd c oworkers 
(Finland) [29]; VEGF-B167 and VE GF-B186. VE GF-B167 has a  s trong a ffinity for 
heparin sulfate, which VEGF-B186 is lacking. Both isoforms can heterodimerize with 
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VEGF-A165 [30, 31]. VE GF-B i s e xpressed m ainly i n m uscle t issue, bot h a lso i n 
embryonic tissues [32]. 
 
Figure 3. VEGF family [33]. 
 
VEGF-C and VEGF–D are lymphangiogenic factors, potently inducing the growth of 
lymph vessels [34-36]. In mice where vegfc has been replaced by lacZ gene; Vegfc-/- 
embryos die during development in utero because of an accumulation of fluid in the 
tissue, due to the lack of lymphatic sprouts and thereby lymphatic vessels [37]. 
 
I would also like to mention VEGF-E. It was found in 1992 b y Dr Lyttle et al in an 
orf virus (OV) which affects sheep, goats and sporadically, humans. This virus causes 
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a br ief a ngiogenic r esponse; c apillary e ndothelial pr oliferation, i n t he s kin. It w as 
reported t hat t he s equence ha s hi gh hom ology of t he h uman V EGF [38]. T he 
molecule was named VEGF-E, and was shown by Professor Shibuya in 1998 to bind 
VEGFR2 but  not  V EGFR1 a nd f urther m ore VEGF-E l ack t he affinity for h eparin 
[39]. Since VEGF-E is not produced in mammals, a t ransgenic mouse was generated 
to expressed VEGF-E, by using a K14 (keratin-14) promoter, it was found that these 
mice ha d m ore reddish s kin c olor a nd t he s ubcutaneous t issue e xhibits a ltered 
although s till o rganized a ngiogenesis. In comparison, i n t he s ame t ransgenic (tg) 
system, K 14:VEGF-A165 tg m ice ha d va rious s ymptoms l ike pe rinatal de ath a nd 
altered vascularization with tissue edema, as a consequence of hyperpermeabilisation 
and s ubcutaneous he morrhage[40]. VE GF-E m ight t herefore b e us eful f or pr o-
angiogenic therapy instead of VEGF-A, since it might not be related such severe risks 
of edema [41]. As a curiosity, one more protein with homology to the VEGF-family 
has been found in snake venom and has got the name VEGF-F [42]. 
 
1.5.1.2 Placental growth factor (PlGF) 
As the name implies, PlGF was found in the placenta and it was shown to have a high 
homology t o V EGF, a nd i s pa rt of  t he V EGF family [ see be low]. T he t wo pr e-
dominant i soforms of  P lGFs a re P lGF-1 (P lGF131), a nd P lGF-2 (P lGF152), a lthough 
there are four PlGF isoforms, named PlGF-1 to PlGf-4 [43-47]. The mouse only have 
one isoform, representing PlGF-2. PlGFs bind VEGFR1, whereas PlGF-2 also binds 
neuropilin ( NrP), due  t o a  21 a mino a cid i nsertion. P lGF-1 a nd P lGF-3 l ack t he 
heparine bi nding dom ain a nd a re t hereby di ffusible, c ompared t o P lGF-2 a nd -4 
which bind heparin [48, 49].  
In the early 90s, PlGFs were found to bind to VEGFR1 but not VEGFR2. Compared 
to VEGF-A, which is a permeability inducer; neither PlGF-1 nor PlGF-2 could induce 
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significant v ascular p ermeability. Further it w as a lso f ound th at th e tw o P lGF 
isoforms could enhance the effect of low but not high concentrations of VEGF [50]. 
 
Surprisingly P lGF n ull mic e w ere h ealthy, f ertile, a nd exhibited o nly s lightly 
decreased r emodeling o f r etinal v asculature an d d ecreased n umber o f v essels i n 
corpora lutea. Furthermore, PlGF-/- mice had an increased level of VEGF compared to 
the wt mouse [51] (worth mentioning is that in the publication the heterodimerization 
between PlGF and VEGF-A in the wt mice was not discussed). In the adult, PlGF is 
expressed i n E Cs, bu t mainly i n t he pl acenta a lthough i t c an a lso be  f ound up -
regulated in malignancies, such as choriocarcinoma. 
 
1.5.1.3 VEGF receptor (VEGFR ) 
I h ave now  de scribed t he g rowth f actors, b ut how  a bout t heir c orresponding 
receptors? T here ar e t hree V EGF receptors. T he V EGFR1 i s d enoted F lt-1, a nd 
VEGFR2 is also known as KDR in humans and Flk-1 in mice, whereas VEGFR3 is 
denoted F lt-4. T he V EGFRs a re a  group of  t yrosine ki nase r eceptors, w hich a re 
activated upon l igand b inding, l eading t o r eceptor di merization a nd a ctivation of  
intracellular s ignaling. D uring th e d imerization th e in tracellular d omains g ets 
phosphorylated and th ereby t rigger th e in tracellular s ignal tr ansduction. T he lig and 
VEGF-A binds both to VEGFR1 and 2, whereas PlGF and VEGF-B binds VEGFR1 
alone. F urther V EGF-C a nd -D bot h bi nds t o V EGFR3, w hich i nduces 
lymhpangiogenesis [52]. VE GF-D also bi nds t o V EGFR2 (with poor  angiogenic 
activity), although only in humans, not in mice [53].  
 
Receptor 1 and 2 have different expression pattern, have different roles to play during 
embryogenesis, give rise to different signal transduction responses [54], and also give 
 14 
rise t o di fferent a ngiogenic r esponses, a lthough, t he f unction of  r eceptor 1 ha s not  
clearly been found out  yet. The f ield contains di fferent and contradictory reports of  
the f unctionality of V EGFR1, w here i t i s c laimed t hat t he V EGFR1 also i nduces 
angiogenic r esponse i n t he s ame f ashion as  t he well-established angiogenic i nducer 
VEGFR2 [55]. V EGFR1 ha s a  hi gher a ffinity f or V EGF-A, c ompared t o V EGFR2 
which ha s l ow affinity, a lthough t yrosine ki nase a ctivity of V EGFR1 i s 10 -fold 
weaker than VEGFR2 [56, 57].  
 
All t hree r eceptors ar e e xpressed o n en dothelial cells, w hereas V EGFR1 i s f urther 
expressed on monocytes/macrophpages, pericytes, SMCs, osteoclasts, dendritic cells, 
bone marrow progenitor cells, hepatocytes, neural cells, and various tumor cells [33, 
56-60] . T he f unction of  t he r eceptor i n t hese c ells i s not  yet defined. V EGFR2 i s 
further expressed on hematopoietic stem cells, neuronal cells, retinal progenitor cells, 
megakaryocytes, os teoblasts, and pancreatic duct cells.  Simultaneous expression of  
VEGFR1 and VEGFR2 in found on c ells in human testicular t issue, Leydig cells in 
the mouse testis, and in the myometrium. VEGFR1 and R2 are expressed on the ECs 
of the embryo (both human and monuse). In mouse, VEGFR2 is first expressed at day 
7.0 on t he m esodermal bl ood i sland pr ogenitors a nd t hen i n t he a ngioblasts 
surrounding the blood islands in the early embryogenesis [4]. At In E7.5 the VEGFR2 
positive cells can be found in the tail region and from where they migrate toward the 
head region and yolk sac, where the cells differentiate to  primitive endothelial cells 
[61]. VEGFR1 is expressed first at day 8.5 in the angioblasts. The expression level of 
the receptors are high, but decreases after day 14.5 to 16.5. The VEGFR2 expression 
levels continue to decrease and diminish at the end of gastrulation [4] and in the adult 
mouse t he V EGFR2 e xpression i s m ostly found i n t he va scular E Cs a nd 
hematopoietic c ells, w hich c ould be  t he pr ogenitors f or E Cs [61]. O n t he c ontrary, 
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VEGFR1 expression is increased in the newborn mouse and in the adult mouse the 
expression level is relatively high [4].  
 
To study the receptor functionality from another point of view, the VEGFR1 (Flt-1) 
null m utant mice di e a t e mbryonic s tage E 8.5-9.0, due  t o a n ove rgrowth of  
disorganized vessels, proving the important role of VEGR1 as a negative regulator of 
vasculogenesis. T he F lt-1 T K m ice, l acking t he t yrosine ki nase dom ain of  t he 
receptor ar e h ealthy w ith r elatively n ormal b lood v essels [62], a lthough t hese m ice 
have a defective migratory response of macrophages toward VEGF-A. VEGFR2 KO 
embryos die at E8.5-9.0 due to lack of vasculogenesis and a hampered hematopoietic 
development [57]. T hese f acts, t hat t he V EGFR1 i s important a s a n embryonic 
inhibitor of  t he va sculature a nd t hat V EGFR2 i s i mportant f or t he i nitiation of  
vasculogenesis, shoves that both VEGFR1 and R2 are essential for the development 
of the vascular blood system. 
 
Figure 3. Positive and negative regulation. (Modified from [33]) 
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1.5.1.3.1 Signal transduction pathways 
Upon ligand binding the VEGFR2 is activated by phosphorylation, this will lead to an 
activation of  phophol ipase C  γ (PLCγ) , w hich i n i ts t urn l eads t o inositol 
trisphosphate (IP3) generation and activation of the protein kinase C (PKC) pathway, 
as well as calcium mobilization, and PKC will also s timulatethe c-Raf-MEK-MAP-
kinase cascade, ending up in DNA synthesis. The VEGFR2 tyrosine kinase activation 
is unusual i n t he w ay t hat t he R as pa thway is not  t ruly a ctivated. F urther, 
phosphoinositide-3 ki nase ( PI3K) pa thway i s a ctivated t hrough t he V EGFR2 
activation, le ading to  c ell s urvival. Interestingly, th e S rc p athway is  a lso a ctivated 
upon VEGF-A l igand binding in ECs lacking the SMC coating, which lead to actin 
cytoskeletal rearrangements and migration. VEGFR1 is not as clearly described as for 
the pr evious r eceptor, w hen i t c omes t o s ignal t ransduction. T he P I3K pathway i s 
activated as  w ell as  P LC γ [57], a nd i t ha s be en f ound t hat IP3 i s g enerated unde r 
certain c onditions [61]. T he r eason i n why t he s ignal t ransduction pa thways f or 
VEGFR1 have not been clearly defined is due to the weak induction of the VEGFR1 
activity in vitro and also because different ligands will give rise to different cellular 
responses.  The ligands do not always bind the VEGFRs alone but also bind the co-
receptors. T hese co -receptors c an be  a nother r eason f or t he c omplexity of  s tudying 
VEGFR1. 
 
1.5.1.4 Soluble VEGFR (sVEGFR) 
VEGFR1 h as a  soluble form, c alled sVEGFR1, which l ack the t ransmembrane and 
intra-cellular parts of the receptor, which is pivotal for the intracellular signaling. The 
sVEGFR1 is found in the human EC, SMC, placental throphoblast, corneal epithelial 
cells, pr oximal t ubular cells of  t he renal e pithelia, a nd activated pe ripheral bl ood 
monocytes. In t he di verse c ell t ypes, s VEGFR1 i s pr oduced a s di fferent s plice 
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variants, s uggesting m ultiple f unctionality. T he different f unctions of  t hese s plice 
variants remains to be elucidated [63]. Further, this soluble receptor is embryonically 
conserved in different species [64], which tells us of its essentiality function in basic 
in vivo biology.  
The functionality of sVEGFR1 is not defined yet, but it is believed to be involved in 
at l east t wo m echanisms: 1 ) t o act  as  a d ecoy-receptor, b y bi nding t he V EGF-A 
molecule, a nd t hereby prevent i t t o bi nd t ransmembrane receptors a nd t ransduce 
further s ignals, a nd 2)  t o he terodimerize w ith t he t ransmembrane r eceptor, a nd 
thereby prevent homodimerization and thus any further signal transduction [63].  
Not only sVEGFR1 are produced by alternative splicing, but also sVEGFR2 and R3. 
Recently sVEGFR2 has been shown to be  secreted in the plasma of  the mouse, but 
also in the human plasma. By the use of several different antibodies directed against 
the s oluble f orm of  V EGFR2, t he r eceptor c ould be  de tected i n c onditioned m edia 
from different human and mouse ECs [65]. sVEGFR2 and R3 have been previously 
shown to inhibit EC proliferation [66-68]. Although not much is known about these 
receptors and further investigations need to be done. 
 
1.5.1.5 VEGFR1 in tumor angiogenesis 
VEGFR1 can be involved in both positive and negative regulation of tumor induced 
angiogenesis.  
When t he t umor cel ls o verexpress V EGF-A, ho modimers of  t he l igand w ill bi nd 
VEGFR2 on t he E C a nd s timulate a ngiogenesis. T umor c ells w hich r elease 
homodimers o f P lGF w ill c ause w eak angiogenic s timuli, d ue t o t he a ctivation of  
VEGFR1. In the case when the tumor is releasing PlGF and VEGF-A from different 
cells, PlGF will homodimerize and bind VEGFR1, and thereby shifting VEGF-A to 
mainly bind VEGFR2, causing a strong angiogenic response, with vessels of typical 
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irregular, and torturous structure with a high amount of vascular plexus formation. In 
tumor c ells t ransformed t o ove rexpress P lGF i t ha s be en s hown, t hat a  
heterodimerization will occur between PlGF and VEGF-A ligands. The homodimers 
will bi nd t he c orresponding r eceptor, w hereas t he he terodimer w ill bi nd t o a  
heterodimerization of the receptors, VEGFR1/2. The receptor shift of the ECs will be 
toward t he r eceptor-heterodimer a nd l ess V EGFR2 hom odimer i s t hus a ctivated b y 
VEGF-A homodimer ligands.  In this scenario, the angiogenic response is very low, 
and the vessels have a so called normalized phenotype [33]. 
 
1.5.1.6 Neuropilin (NrP) 
Neuropilins a re br oadly expressed, t ransmembrane glycoproteins and f unction 
primarily as  co-receptors for semaphorins, which are r esponsible for axon guidance 
during t he d evelopment of t he n ervous s ystem [69]. F urther, N P al so ac ts as  a  co-
receptor fo r VEGFRs. T here are t wo i soforms, N P-1 a nd N P-2, a nd bot h a re 
expressed on E C, but differ in which l igands they bind. Both NPs bind VEGF-A165, 
VEGF-B, VEGF-E, and PlGF-2 [4, 69, 70]. VEGF-A145 only binds NP-2 and VEGF-
A121 does not bind the NPs at all. Transgenic mice overexpressing NP-1 had increased 
amounts of capillaries, dilated blood vessels, and hemorrhage. NP-1-/- ko mice, die at 
E12.5-13.5 due to impaired cranial and spinal fibers, neural vascularization, irregular 
development o f b ranchal ar ch arteries, l arge vessels, an d d isorganized v ascular 
network in t he yolk s ac. N P-2-/- on t he ot her hand, di d not  ha ve a ny a bnormal 
vasculature. In mice where both NPs are KO (NP-1-/- NP-2-/-) they die in E8.5 with 
sever defects of the blood vasculature in the yolk sac and in the embryo, with higher 
severity of vascular malformations compare to the single KO, proving that both NPs 
are important for the development of the vasculature[69, 70]. 
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1.5.1.7 Fibroblast growth factor (FGF) 
Fibroblast gr owth f actor ( FGF) f amily ha s t wo pr e-dominant i soforms know n a s 
acidic F GF an d b asic F GF, n amed af ter t he p urification ex traction [71]. T hey are 
presently cal led FGF-1 and FGF-2, respectively. The human FGF family consists of 
23 different isoforms. FGF does not have the cytoplasmic sequences for extracellular 
transport and the mechanism behind extracellular release of FGFs is still not known 
[72]. However what is known is that the FGF ligands have a high affinity for heparin 
sulfate proteoglycans (HSPGs), which binds both FGF and one of the FGF receptors 
(FGFRs).  The extracellular FGFs are deposited in the HSPGs. Alone the HSPG have 
no biological e ffect on F GF, although in contact with the FGFR, the FGF l igand is 
efficiently ‘presented’ to and bound by the receptor. A complex is formed consisting 
of HSPGs, l igands and receptors. The l igand-bound receptors will dimerize, leading 
to a utophosphorylation, and t his w ill be  followed b y a r apidly i nternalization [73]. 
Activated s ignal t ransduction of  t he r eceptors i ncludes R as-Src-PI3K, a nd t he P LC 
pathways [72]. FGF-2 deficient mice have cerebral cortex impairments, yet the mice 
are viable. F urther, t hese m ice h ad r egular v essels b ut a d ecreased b lood p ressure 
[74]. By us ing an adenovirus expression vector encoding of dominant-negative and 
truncated form of FGFR1 in mice embryos, it was demonstrated that these abnormal 
embryos ha d extra va scular de velopment a nd t hat F GFR1 i s ne eded f or t he 
maintenance of the mature vasculature in the embryo [75]. 
 
The receptors are tyrosine kinases and are expressed on most cell types [76], and have 
a wide range of biological roles, such as angiogenic activity, stimulation of stem cell 
differentiation, tissue repair, neurotrophic activity, and osteogenesis [77]. FGFRs are 
often e xpressed i n t umors, a nd ove rexpression a nd e xpression of  m utated f orms of  
FGF is also common in tumors [78]. FGFR activation of ECs leads to angiogenesis. 
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FGF-2 ove rexpression i n non -small cel l l ung c ancer an d b ladder carcinoma, have 
correlated with poor prognosis [79, 80].  
 
1.5.1.8 Platelet derived growth factor (PDGF) 
The Platelet derived growth factor (PDGF) family consists of four isoforms, PDGF-
A, -B, -C, a nd –D. T he i soforms ex ist i n their act ive an d ex tracellular f orm as  
homodimers or as t he heterodimer P DGF-AB. T he l igand bi nds i ts r eceptor, t he 
PDGF receptor (PDGFR), which has two isoforms PDGFRα and PDGFRβ. PDGF-A, 
-B, and -C binds to the PDGFRα and PDGFRβ are bound b y the B- and C-chains it 
gives r ise t o d ifferent receptor-ligand combinations. T he i ntra c ellular pa thways 
activated by the two receptors give rise to similar but not identical cellular responses. 
The activation of  PDGFRαβ heterodimers and hom odimers of P DGFRβ causes 
chemotactic responses of  S MCs a nd f ibroblasts. O n t he c ontrary, i nhibition of  
chemotaxis i s cau sed b y homodimers of  the P DGFRα receptor [8]. T he i nvolved 
signal t ransduction pathways a re t he P I3K and P LCγ which are a ctivated i n 
chemotaxis. The Erk-MAP and Src pathway are induced in cell proliferation. Further, 
the R as pathway and S TAT family ar e act ivated upon l igand-receptor bi nding. The 
receptors ar e al so i nactivated b y p eroxiredoxin type II, a c ellular pe roxidase t hat 
eliminates H2O2 [81]. 
 
It h as b een d emonstrated t hat t he en dothelial t ip cel l ex presses high a mounts of  
PDGF-B mR NA, s imultaneously with VEGFR2 m RNA [82]. A s de scribed a bove, 
VEGFR2 o f th e tip  c ell is  s timulated b y th e c hemoattractant. T he r ole o f th e 
expressed PDGF-BB is to recruit the pericytes or SMCs, to stabilize the endothelial 
stalk cells, which are in close relation to the tip cell. PDGFRβ are expressed by mural 
cells and s tromal cell, both in healthy tissue and in tumor. The f irst time PDGFRβ  
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was d escribed w as i n co lorectal can cer year 1 993 [83], a nd ha s be en s een i n m ost 
solid tumors. Because, the PDGFRs are so widely expressed in different tumors, they 
are the focus of  e xtensive r esearch, a nd f urther the r eceptors a re al so t argeted i n 
cancer therapy. The mechanism of mural recruitment/ablation of tumor vessels is not 
fully understood [8].  
 
The P DGFs are ex pressed by many e pithelial c ells i n di fferent or gans a nd t he 
receptors in the nearby mesenchymal cells during embryonic development [84]. Even  
embryonic development it has been shown that PDGF and PDGFRs are involved in 
vessel m aturation a nd r ecruitment of  pe ricytes. In t he P DGF-B knock out  mice 
(PDGF-B-/-) the vessels lack the pericyte coverages. These vessels were torturous, had 
micro aneurysms (a balloon l ike bulge structure filled with blood), and had variable 
diameter. In comparison, the wt mice had s traight vessels of  regular diameter.  The 
mice have hemorrhage and edema, and they die during late embryogenesis [85, 86] . 
Overexpression o f P DGFR i n o varian cancer h as b een associated with a  poor  
outcome [87].  
 
1.6 CANCER-ASSOCIATED RETINOPATHY (CAR) 
Retinopatathy i s a  non -inflammatory damage o f t he retina o f t he e ye. T here a re 
several different types of retinopatghies, including retinopathy of prematurity (ROP), 
diabetic retinopathy (DR), and cancer-associated retinopathy (CAR).  
ROP can occur in infants born prematurely and i t can progress into blindness. ROP 
will oc cur i n t wo pha ses: P hase 1 ) th e r etina is o nly p artially vascularized w ith 
vessels lacking in the peripheral zone up. When the eye is growing, the retina will not 
receive the correct amount of nutrient, growth factors, or oxygen; and it will cause a 
hypoxic environment. Phase 2) the hypoxia will increase VEGF-A release and induce 
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angiogenesis of  l ow qua lity v essels [88, 89]. T he t reatment u sed o f a cute-CAR, i s 
laser t herapy for r emoval o f t he avascular ar eas, al though l ess destructive t herapies 
are under evaluation, such as intravitreal anti-VEGF (bevacizumab) therapy, which is 
already used in adults [89]. 
DR will affect almost all diabetic patients after ten-years of t ime. The DR is a long 
process which starts with a vasoregression initiated by pericyte ablation, and it seems 
like Ang-2 i s involved in this process. The vasoregression causes h ypoxia and then 
retinal a ngiogenesis oc curs t o r estore t he ox ygen de livery, c ooperated b y VEGF-A 
and Ang-2 [90]. The blood-retinal barrier breaks down and it causes plasma leakage 
into t he c entral pa rt of  t he r etina, c ausing s welling of  t he r etina. F urther, v ascular 
growth into the vitreous can hemorrhage the vitreous and all these defects can cause 
vision failure [91]. 
 
1.7 THERAPY  
 
1.7.1 General cancer therapy 
Cancer t herapy c an r oughly be  di vided i n t o t wo g roups of l ocal t herapies an d 
systemic th erapies. T he lo cal th erapies a re f urther d ivided in to: 1 ) S urgery is  to  
remove either the t umor or  t issues. T hese t issues a re r emoved i n pr evention, s ince 
they most likely could turn into a tumor. 2) Radiation therapy, which is often used in 
combination w ith chemotherapy. R adiation th erapy is  to  k ill th e c ancer cells either 
before or after the main treatment. As an option, it is also used to decrease the size of 
a tumor when surgery is not possible, such as in some areas of the brain. It can also be 
an al ternative t o d ecrease pain. 3 ) Tumor ablation, which is  to  k ill the cancer c ells 
locally, without surgery or radiotherapy.  This group includes radiofrequency ablation 
through e lectrodes. A lso, i t i ncludes a rterial c hemo- or mechanical-embolization, 
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which refers to c losure of  a major artery to interrupt the blood supply of the tumor 
and simultaneous delivery of chemotherapy to the specific area [i].   
Systemic t herapies i nclude chemo-, t argeted-, ho rmone-, and biological t herapy. A ) 
Chemotherapy w orks b y c hemical de struction of  t he D NA or  R NA m achinery or 
other s tructures t hereby interrupting t he pr oliferation a nd/or s urvival of  t he c ancer 
cells. B) Targeted therapy acts by targeting specific molecules, exciting in both tumor 
and he althy t issues. The targeted molecules s uch w hich are o ften o verexpressed or 
expresses in a modified form by the tumor. These targeted molecules are often critical 
for tumor growth and survival. C) Hormone therapy is directed or indirect toward the 
tumors, which needs hormones to grow, and successfully used in breast and prostate 
cancer, r espectively. D) B iological t herapy o r b iotherapy i s an  i n-direct c ancer 
therapy, which works by targeting the immunesystem, which in turn could act on the 
cancer cells [i]. 
 
Also worth mentioning is palliative therapies. Palliative therapy or palliative care is to 
improve life quality, by removing pain and other discomfort symptoms [i].  
 
1.7.1.1 Chemotherapy: 
Chemotherapeutic a gents w ork t hrough t he i nterference w ith D NA s ynthesis or  
function, and c an be  classified as a lkylating a gents, antimetabolites, anthracyclines, 
platinums, or  a nti-tumor a ntibiotics or  non -DNA i nterference s uch as , m ono-clonal 
antibodies, or plant alkaloids [ii].  
Alkylating chemotherapy, w hich i s t he m ost c ommon s trategy us ed anti-cancer 
treatment, act by crosslinking of the DNA strands to cause abnormal base pairs, and 
thereby pr evention t he c ell di vision pr ocess.  A lkylating agents ar e u sed i n a l arge 
variety of cancers and are most efficient in slow growing cancer, such as solid tumors 
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and l eukemia. S ide-effects of  l ong-time us e c an be  i nfertility o f bot h s exes a nd 
secondary cancers, such as Acute Myeloid Leukemia. Cyclophophamide (CTX) is an 
example of an alkylating agent [ii]. 
Anti-metabolites work by incorporation in the DNA or RNA and interfere with the 
process of  c ell di vision. T he s tructures of  the c ompounds i n this g roup of  
chemotherapeutics ar e s imilar t o s tructures n aturally oc curring i n t he bo dy s uch as 
vitamins, a mino a cids, or  pr ecursors of  D NA or  R NA.  A nti-metabolites ar e 
commonly us ed i n treatment o f leukemia, an d also i n s ome cas es o f tumors of  t he 
gastrointestinal tract, ovary, and breast [ii]. 
Anthracyclines form free radicals which break the DNA strands, or integrate in the 
DNA or RNA between the base pairs, or inhibit topoimerase II and thereby prevent 
DNA t ranscription a nd r eplication.  T he a nthracyclines are d erived f rom t he 
Streptomyces b acteria. This g roup of  chemotherapeutics i s t he m ost e fficient a nti-
cancer t reatment an d t hey are u sed i n a l arge variety of t umors s uch as  b reast, 
ovarian, leukemia, and lung cancers. Side effects of these drugs are quite severe; the 
heart muscle can be damaged [92, 93]. Anthracyclines are sometimes classified as a 
separate own group of chemotherapeutic but also sometimes are listed as a subgroup 
of the anti-tumor antibiotics [ii]. 
Anti-tumor antibiotics are also d eveloped f rom S treptomyces b acteria, an d h ave 
many d escribed s imilarities as an thracyclines. T hese ch emotherapeutic a gents form 
radicals, breaking the DNA strands, stopping proliferation, although not presumably 
killing the cell. Anti-tumor antibiotics are used widely for the treatment of different 
cancers, s uch as  t esticular cancer and Hodgkin’s l ymphoma. T reatment i s us ually 
combined with other chemotherapeutic agents. The most common s ide-effect seems 
to be limited to the lungs [ii].  
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Platins cross-link s ubunits of  D NA and p revent various DNA f unctions. C isplatin 
was first generated but had high toxicity and can give rise to damaged kidneys. The 
second-generation, c alled C arboplatin is  le ss to xic b ut s till h as s ide e ffects o n th e 
kidneys. A  t hird ge neration, O xilplatin ha s e ven l ess s ide-effects h owever, i t can  
cause s evere n europathies. C isplatin i s u sed i n t he t reatment o f t esticular can cer 
(highly s uccessful), non -small cel l l ung cancer, s mall cel l l ung cancer, l ymphomas 
and m yelomas. Another dr awback of  C isplatin that is  it  to s ome extent cau ses 
resistance.  Since Carboplatin is so similar in reactivity, it is used in the same types of 
cancers, but  i n pa rticular ova rian c ancer. O xilplatin i s c apable of  o vercoming 
cisplatin resistance and is used in colorectal cancers and is in clinical trials for several 
other cancer types [94] [ii].  
Monoclonal antibodies work i n di fferent w ays, b y bi nding antigens either in t he 
tumor w hich c an t hen be r ecognized b y t he i mmune s ystem, or  by binding to 
important growth f actors or  t heir r eceptors a nd t hereby p revent t he t umor g rowth. 
These a ntibodies a re us ed i n c olon, he ad, ne ck, l ung, a nd br east c ancers [ii]. An 
example of these antibodies is Bevacizumab (Avastin). 
Plant alkaloids are d erived f rom p lants an d ar e c ell-specific, Th ey work b y 
interfering t he cel l-cycle i n di fferent w ays. T he plant a lkaloids a re f urther gr ouped 
into four categories and they are used in leukemia and many other cancers [ii]. 
 
1.7.1.1.1 Carboplatin 
Carboplatin (Paraplatin®) is  used as in itial o r palliative tr eatment o f non-small cell 
lung c arcinoma, ovarian carcinoma, and lung, bl adder, h ead and ne ck, a nd cervical 
cancer, and others. Even though carboplatin was developed to reduce the side-effects, 
treatment it still leads to severe bone marrow suppression, with decreased white blood 
cell counts, and can cause anemia [94, 95] [iii]. 
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1.7.1.1.2 CTX 
One of  t he m ost s uccessful a nti-cancer dr ug i s C yclophophamide ( CTX or  
Cytoxan®). It is used in treatment of lymphomas, sarcomas, and breast, germ cell, anf 
testicular can cer. C TX works b y crosslinking the DNA, and in t his way interfering 
with cell proliferation. High dose CTX t reatment the s ide-effects i nclude bone  
marrow s uppression; c ausing l ow bl ood c ounts, w hich c an g ive r ise t o a nemia, 
bleeding, and i nfection. F urther C TX c an s uppress the immu ne s ystem a nd is  
therefore us ed i n a utoimmune di seases. S ide-effects s uch as  l eukopenia, 
thrombocytopenia, a nemia, c ardiotoxicity, and gonadal f ailure ( mostly f or f emales) 
are common in high-dose administration of CTX [96, 97] [iii]. 
 
1.7.2 Anti-angiogenic therapy: 
The an ti-angiogenic t herapies can generally be d ivided i nto t hree groups. 1 ) 
Monoclonal antibodies, w hich are directed against s pecific p ro-angiogenic f actors 
and/or t he c orresponding r eceptors. The Food and D rug A dministration ( FDA) of  
USA has approved Bevacizumab and Cetuximab. 2) Small molecule tyrosine kinase 
inhibitors (TKIs) of  a multitude of  pr o-angiogenic growth f actor r eceptors. T hree 
TKIs used clinically are Imatinib, Sunitinib, Sorafenib, and Vandetanib. 3) Inhibitors 
of mTOR, t he m ammalian t arget o f r apamycin in t he P I3K-AKT-mTOR s ignaling 
transduction pa thway. 4 ) A group o f ot her anti-aniogenic a gents, e. g. t argeting 
Endostatin and Interferon alfa [98] . 
 
1.7.2.1 Bevacizumab 
Bevacizumab ( Avastin®) i s t he f irst a pproved anti-angiogenic a gent. Used i n t he 
treatment o f m etastatic colon o r r ectal can cer, non-squamous, non -small c ell lu ng 
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cancer, metastatic breast cancer, glioblastoma and of metastatic renal cell carcinoma 
and is mostly used in combination with chemotherapy. Therefore, it is generally not 
known w hether t he s ide-effects ar e c aused t he chemotherapeutic a gents o r b y t he 
monoclonal a ntibody. The r eversible s ide-effects, w hich d isappear af ter end of  
treatment, generalized w eakness, l ow w hite bl ood c ell c ounts, pr oteinuria, na usea, 
pain, a nd c onstipation. B evacizumab w orks b y targeting V EGF-A, and t hereby 
preventing it from binding to its receptors, and further thereby angiogenesis [98, 99] 
[iii]. 
 
1.7.2.2 Imatinib 
Imatinib M esylate ( GleevecTM or S TI-571) w as th e f irst s mall molecule T KIs 
approved. Imatinib is used in the treatment of chronic myelogenous leukemia (CML), 
gastrointestinal s tromal tumors w hich a re pos itive f or c -kit, a nd 
myelodysplastic/myeloproliferative d iseases a ssociated w ith P DGFR. Side-effects 
include l ow bl ood counts, e dema, and he morrhage. Imatinib i s a n i nhibitor of  
PDGFR, c-kit, CSF-1R, and Abl (a cytoplasmic and nuclear protein tyrosine kinase). 
Imatinib antagonizes the ATP binding site of the tyrosine receptor, preventing further 
intracellular signal transduction [98, 100, 101] [iii]. 
 
1.7.2.3 Sunitinib  
Sunitinib (Sutent® or SU11248) is a small molecule inhibitor and is used in treatment 
of gastrointestinal s tromal t umor ( GIST) and a dvanced r enal c ell c arcinoma. T he 
generally low side-effects may include fatigue (predominantly), high blood pressure, 
and/or l ow bl ood c ounts. A s a  c uriosity, t he pa tient m ay gain a  s kin di scoloration, 
which is possibly due to the strong yellow colour of the drug. Personal observations: 
the mice treated with Sunitinib have distinct yellow colour of the urine compared to 
PBS t reated m ice. S unitinib is  a  mu lti-targeted r eceptor t yrosine k inase ( RTK) 
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inhibitor, t argeting the VEGFR, PDGFR, RET, colony-stimulating factor-1 receptor 
(CSF-1R), and the hematopoietic markers Flt-3 and c-kit [98, 102-104]. As Imatinib, 
Sunitinib i nhibits t he tyrosine ki nases by c ompeting w ith A TP to  b ind th e 
intracellular domain, and thereby stop further signal transduction [104] [iii]. 
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2 AIMS 
 
The general aim of this thesis is to increase our understanding of the mechanisms of specific 
angiogenic growth f actors a nd t heir function in tumors and cancer as sociated d isease, an d 
further t o und erstand t he e ffects of  anti-angiogenic dr ugs i n c ombinations w ith 
chemotherapy.  
 
Specific aims: 
1) To study the cross-talk between various angiogenic growth factors in promotion of 
tumor growth and metastasis (paper I) 
2) To study the role of the VEGFR1 specific ligand PlGF in tumor angiogenesis, 
normalization and tumor growth (paper II) 
3) To investigate the angiogenic growth factors and their receptors in cancer-associated 
disease (paper III) 
4) To study non-tumor targets of anti-angiogenic drugs (paper IV) 
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3 METHODOLOGY 
 
3.1 IN VIVO ASSAYS 
 
Classical tumor models or xenografts were p erformed b y t umor cel ls i njection 
subcutaneously into the mid-dorsal region of the mice. When tumor reached a certain volume 
or a fter a f ixed num ber o f da ys, the m ouse w as e uthanized, a nd bl ood, tumor a nd ot her 
tissues w ere co llected. I n the metastasis assay, t he t umor w as r emoved an d sk in st itched 
together o f the anesthetized m ice, an d a fter a f ew w eeks t he m ice w ere eu thanized an d 
examined f or m etastasis. T he tumor cell lines, have b een d escribed p reviously, ar e 
transfected w ith cD NA co ding f or a human g rowth f actor cloned i nto a v ector c ontaining 
EGFP [105]. The cells overexpress growth factors such as VEGF-A165, PlGF-1129, and PDGF-
BB. 
 
 This type of tumor models (syngeneic, orthotopic, or as xenografts) are a broadly used in 
the medical research, where the tumor effects of anti-cancer drugs can be studied. Tumor 
growth is studied by measuring the tumor size, over a period of time, which is quickly and 
easily pe rformed by a  c aliper. This i s not  po ssible in t he or thotropic model, w here t he 
tumors ar e n ot reachable a nd t he t umor si zes o f d ifferent individuals w ill be compared 
after sacrificing the mouse. Thereby the progression of  the cancer can be followed. The 
vascular structures and other tissue-specific changes can be studied post sacrifice (paper I, 
II, III, and IV). When the primary tumor is removed, the mouse (or patient) may not heal 
from t he can cer, b ut tumor cel ls may st ill r emain an d cau se d angerous metastasis. The 
described metastatic model gives us proves for just how aggressive some overexpressing 
growth factors are in comparison to others (paper I).  
 
The vascular permeability and perfusion assays, which were developed in this thesis, were 
performed when the tumors had reached a s ize of maximum 1 c m3, followed by a  tail vein 
injection of lysine-fixable rhodamine labeled dextran (LRD) of different molecular sizes. The 
small s ize o f 7 0 k Da c irculated f or 5  m inutes an d t hen t he tumors w ere c ollected an d 
immediately placed in a paraform aldehyde (PFA) solution, after whole mount staining and 
visualization in the confocal microscope the extravasated dextran could be analyzed. In the 
perfusion assay, 2000 kDa dextran were injected and tumors were collected after 15 minutes, 
following the same procedure as previously described, and analyzing the perfused vessels.  
 
 Permeable agents of d ifferent m olecular w eights, o ne su ch a re E vans B lue, h ave b een 
used f or t he s tudy of  the v essel p ermeability, al though af ter q uantifications o f t he 
extracted d ye, i t r eveals l ittle o f t he ac tual m icrovessel s tructure-function r elationship. 
When injection of fixable and f luorescent dyes, such a s LRD, it is possible t o stain the 
vessels, v isualizing t he areas w here the leakage h as o ccurred an d also t o q uantify t he 
number of perfused vessels, containing LRD in an accurate manner (paper II and III).   
 
Mouse corneal micropocket assay was carried o ut b y m ixing t he g rowth f actors w ith 
sucralfate (a heparin-binding slow release substance) into a pellet, and then placing the small 
pellet i n a m icropocket i n t he co rnea o f t he m ouse [106]. The e yes w ere ph otographed 
regularly an d lastly t he co rneas w ere co llected and the v essels w ere v isualized b y w hole 
mount staining and confocal microscopy.  
 
 The co rnea i s an  av ascular an d t ransparent t issue. B y p lacing an  ag ent w hich i nduces 
vascular g rowth into t his t issue; a ll of the v essels v isualized ar e n ewly f ormed ( by 
angiognesis). F urther by  monitoring the v essels ov er long t ime, t he s tringency of  the 
particular ag ent is remarkable. S ome g rowth f actors w ill h ave o nly i mmediate time 
induction of vessels such as PDGF-BB, whereas other growth factors, such as PDGF-BB 
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in combination with FGF-2, will last a long time, even a year after the pellet implantation 
and even after the loss of the pellet [107] (paper I). 
 
 
Immunihistochemistry w ere p erformed b y u sing t hree d ifferent as says. Whole mount 
staining was used on PFA fixed fresh tissue, which were sliced into small pieces, from non-
necrotic regions and digested in proteinase K, fixed in methanol and blocked in milk 
overnight. The pieces were then incubated in the primary antibody overnight, for an example 
(the most c ommonly used antibody i n this thesis) rat a nti-mouse CD31 (PECAM-1, B D 
Bioscience). After rigorously washing followed by blocking, the pieces were incubated with a 
secondary antibody e.g. Alexa 555-labeled goat anti-rat (Invitrogen). Further the tissues were 
washed a nd m ounted i n Vectasheild m ounting m edium ( Vector L aboratories) a nd l astly, 
visualized and analyzed by confocal microscopy (Zeiss or Nikon) (paper I, II, III, IV). H&E 
were p erformed on  t issues f ixed i n P FA, d ehydrated a nd e mbedded i n pa raffin. These 
samples were sectioned and immunostained by the use of biotinylated monoclonal antibodies. 
Further, peroxidase activity was developed with diaminobenzidine (Vector Laboratories) and 
the s amples w ere c ounterstained by  he matoxyling a nd e osin and l astly a nalyzed i n a  l ight 
microscope ( paper I  a nd IV). Immunofluorescent staining, so called Cryosection staining, 
was performed on t issue which immediately upon collection had been placed in a cryomold, 
and t hese t issues w ere sectioned in a cryostat, washed an d blocked i n serum, f ollowed b y 
incubation w ith sp ecific a ntibodies. F urther w ashes of t he se ctions followed by seco ndary 
antibody incubation a nd l astly mounting. T he t issues were e xamined unde r the c onfocal 
microscope (paper I).  
 
 Whole mount s taining is a widely used method to stain large 3-dimentional areas of the 
tissue. H &E an d cryosection st aining ar e p erformed o n v ery t hin s lices, esp ecially t he 
cryosection w hich i s a n a dvantage i f single cells ne ed t o be v isualized and q uantified. 
With the confocal microscope it is possible to visualize depths, which has limiting abilities 
in other types of microscopes. The disadvantage with the whole mount staining is the time 
consumption and that the s amples h ave t o b e us ed w ithin approx. 2  m onths a fter 
dissection of the mouse. The paraffin- and cryo-embedding will last for years. By the use 
of different antibodies of different species, it is possible visualize three different targets, in 
one p icture. F or ex ample, it is p ossible to stain en dothelial cells, S MCs, an d pericytes 
simultaneously.  
 
 
3.2 IN VITRO ASSAYS 
 
Cell isolation of primary cells was performed by using fresh lung tissue, to isolate pericytes. 
Aorta tissue was used to isolate SMCs. Tissues were collected and immediately resected into 
small p ieces w hich w ere digested b y co llagenaseII (Invitrogen). The red b lood ce lls w ere 
lysed in ammonium chloride lysing reagent (BD Pharmingen). The cells were then incubated 
with pr imary antibodies (e.g. NG-2 for the pericytes) followed by a  secondary f luorescent-
labeled a ntibody a nd t he c ells w ere sorted w ith F luorescent-activated ce ll so rting ( FACS) 
(Becton Dickinson). The sorted cells were then cultured. For verification of the sorted cells, 
cell staining was performed, where the cells were seeded out and grown on coverslips and 
then stained with primary and a fluorescent secondary antibody, followed by visualization in 
the fluorescent microscope (Nikon) (paper I and IV). 
 
 Isolating primary cells is of value, since they will act more natural than cell lines, which 
are m odified t o av oid senescence. I solated primary cel ls w ill q uickly l ose t heir in vivo 
characteristics, by differentiation or entering senescence after a few passages. Therefore it 
is important to use the cells in experimental settings with as low passage number as 
possible. The markers used to separate the cells are of high importance as a marker needs 
to be  c hosen, which will not be  e xpressed on a nother c ell type i n t he s ame t issue. The 
FACS is a  flow sorting technique, where single cells are separated and collected f rom a 
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heterogeneous c ell popu lation. The F ACS s eparation i s e fficient, a lthough not  100 % 
reliable. A few unwanted cells might appear in the culture and therefore it is important to 
further stain and confirm the newly sorted cells. 
 
Western Blot was performed by treatment of cells with different growth factors at various 
time points. The cells were washed and lysed, followed by centrifugation and the 
supernatants, containing the proteins were collected. Equal amounts of proteins (determined 
by a modified Lowry method (Bio-Rad) and BSA as standard were loaded into gels 
(SDS/PAGE, Novex) and transferred onto nitrocellulose membranes and further blocked 
(BSA) overnight, followed by a primary antibody incubation overnight. Further, after 
washing the membranes, they were incubated with peroxidase-coupled secondary antibodies 
to reveal the bands and photographed in a Lumi-Imager. For the loading control β-actin (anti-
β-actin, Sigma-Aldrich) was used (paper I). 
 
Proliferation and migration 
The proliferation assays was p erformed b y seed ing o ut c ells in a plate w ith o r w ithout 
growth factors after 12 hours the medium was changed and new growth factors were added to 
some of  the wells. The cells were incubated for another 60 hou rs and then the proliferated 
cells were counted in a Coulter counter (Beckman Coulter) (paper I). The migration assay or 
chemotaxis assay was performed in a classical Boyden chamber. Cells either pretreated or 
non-pretreated with growth factors were seeded in the upper chamber and a filter was placed 
in be tween the cells and the l ower chambers in which t here were medium with or  without 
growth factors. After 4 hours the migrated cells on the lower side of the membrane was fixed, 
stained, and mounted, followed by a  quantification of the cells through a  light microscope. 
The number of migrated cells was counted as a criterion for chemotactic stimuli (paper I). 
 
 One of the first steps in angiogenesis is the proliferation of ECs and later mural cells. To 
measure the induction of proliferation by different angiogenic growth factors, we used a 
simple cell counting assay, which measured by the number of cells that are dividing. The 
time of a cell cycle for most EC types are in the range of 18-26 hours. Therefore we pre-
treated the cells with one growth f actor for 12 hours, and then added the next round of 
growth factors, before the first d ivision. This g ives the cells a chance to respond t o the 
first factor, in our case causing a changed receptor expression before being exposed to the 
second. The cells are then left to be able to divide a few rounds, before counting the cell 
number. T he C oulter c ounter i s an e lectronic particle co unter which i s u sing a size 
parameter for counting.  
 Another early step in the process of angiogenesis is EC migration toward a chemotactic 
gradient, into the perivascular stroma. Further, a mural cell migrates in connection to the 
ECs. We u sed a classical transmembrane in vitro assay. The advantage of this system is 
the m igration o f cel ls d ue t o a co ncentration g radient, an d t he r esult can  b e easi ly 
measured by counting the cells. The incubation time, is 4 hours, which is short enough for 
the cells to migrate, without any misleading proliferative effect. Within these 4 hours the 
gradient should not  change s ignificantly, but  a fter longer t ime osmosis might occur and 
can destroy the gradient. Chemokinesis, the random movement of cells, will be counted as 
a ba ckground, and subtracted from the counted value such that the final volume will 
indicate the number of migrated cells due to chemotaxis. We used cells which were both 
non- and pre-treated with growth factors, to see whether the pre-treatment and the 
chemotactic factor had a higher migratory response, compared to the non-pre-treated cells. 
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4 RESULT AND DISCUSSION 
 
4.1 FGF-2 AND PDGF-BB SYNERGISTICALLY PROMOTE TUMOR 
ANGIOGENESIS AND METASTASIS 
 
Angiogenesis i s i nduced b y VEGF-A, but  t umors pr oduce a  di versity of  ot her 
angiogenic f actors a nd i n s ome c ases no e xpression of  V EGF-A c an b e d etected. 
Previously Cao et al reported that the combination of  VEGF-A with FGF-2 or  with 
PDGF-BB, gave no f urther a ngiogenic response i n t he c ornea, whereas a n 
combination of  F GF-2 a nd P DGF-BB i nduces s evere an giogenesis, w hich l asted 7  
months after pellet implantation (which was lost at day 12 pos t operation). Treating 
the mic e w ith V EGFR-2 ne utralizing a ntibodies, di d not  de crease t he angiogenic 
response of  t he c orneas [ 1]. T hereby i t w as s hown t o be  a  V EGF-A i ndependent 
mechanism.  
 
In t his pa per, w e s how a  s ynergistic i nteraction b etween t wo an giogenic g rowth 
factors, affecting the endothelial cells (ECs) and smooth muscular cells (SMCs) in a 
reciprocal a ction t o i nduce t umor n eovascularization a nd m etastasis. Tumors of  
mixed t umor c ells, ove rexpressing e ither FGF-2 o r P DGF-BB, r espectively, g rew 
with increased growth rate compared of each tumor cell type alone. Tumors give rise 
to vi sual pul monary m etastasis i n 30%  of  t he m ice, but  a fter hi stological a nalysis, 
tumor cells in the lungs could be found in as much as 44% of the mice, whereas none 
could be found in the other groups, of control or single factor expression. The tumor 
vessel s tructure ha d a r emarkable changed phe notype, with huge  i rregular va scular 
plexus a nd tip c ells a ll over t he m icro ve ssels. I nterestingly, t he S MCs w ere less 
attached to the vessels, considering PDGF-BB is an SMC attractant, when expressed 
by t he E Cs. A lthough o ne c an s peculate, t hat i n t he t umor t issue t he P DGF-BB i s 
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expressed a ll ove r t he t issue i n a  non -gradient manner, w hich doe s not  m akes t he 
SMCs r espond i n a  regular m anner. In t he c ombined FGF-2 and P DGF-BB 
expressing tumors, t he S MCs have a  s lightly i ncreased association with t he vessels 
compared t o t he P DGF-BB group a lone. A lthough t he c ombined g roup ha s 
significantly decreased vascular association of SMCs compared to the vector.  
The question now, i s w hat actually h as happened to t he mural cells, s ince t hey are 
very important for the vascular support and functionality. In vitro experiments were 
performed, such as proliferation and migration, since it is the first steps in the process 
of angiogenesis. ECs had an increased proliferation due to FGF-2 s timuli, but  not a 
migratory effect. P DGF-BB do es not  i nduce any di rect e ffect on ECs, but  he re w e 
show t hat, pr e-treatment w ith F GF-2, f ollowed b y P DGF-BB t reatment ( as a 
chemoattractant) induced ECs migration. Comparing to the SMCs, pre-treatment with 
PDGF-BB followed b y a tr eatment w ith F GF-2 i ncreased t he pr oliferation but  not  
migration. FGF-2 further increased the migratory ability of the SMCs. Here we have 
an i ndication t hat E Cs which e xpress F GFR1 w ill pr oliferate upon F GF-2 r eceptor 
binding but  ne ed t he pr esence of  P DGF-BB f or m igration. O n t he ot her ha nd t he 
proliferation of SMCs needs activation by the PDGF-BB pathway, followed by FGF-
2 stimulation, which confirms the previous findings that in SMCs PDGF-BB induces 
FGF-2 release and thereby FGFR1 activation [2]. How is the ECs response of growth 
factor s timuli? When t he pr omoters o f P DGF r eceptors α and β, respectively, h ad 
been fused with a luciferase gene as a reporter system, then the promoter activity of 
both r eceptors w ere i ncreased upon  t reatment with F GF-2. F urther i n comparison, 
when the SMCs were treated with PDGF-BB the FGFR1 promoter had an increased 
activity. Taken together, these result shows that upon PDGF-BB stimulation of SMCs 
it w ill c ause a  FGFR1 e xpression. T he E Cs w ill e xpress t he P DGFRs upon FGF-2 
stimulation. 
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To f urther v alidate th e findings, th e mR NA e xpression w as d etected v ia in  s itu 
hybridization of  c orneas, a nd s howed t hat the FG F-2 i nduced va sculature ha d 
elevated h igh l evels o f PDGFR ex pression, w hereas t he P DGF-BB i nduced bl ood 
vessels ha d r elatively l ow l evels of  t he r eceptors, i n c omparison o f t he c ontrols. 
Lastly, a fter t he r eceptor a ctivation, t he s ignal t ransduction pathways a re t o be  
elucidated.  Here w e s how, i n act ivated E Cs, F GF-2 p re-treatment followed b y 
PDGF-BB treatment, activated the ERK-pathway leading to DNA transcription. 
 
The m echanism be hind t he s evere m alformation of  t he t umor va sculature, a nd 
increased incidence of metastasis in mice carrying tumors expressing both FGF-2 and 
PGDF-BB is due to FGF-2 will bind and activate the FGFR1 on the ECs, which leads 
to pr oliferation, but  a lso t o a n e xpression of  PDGFRs, a nd t heir a ctivation upon 
PDGF-BB bi nding l ead to E C m igration. T he E Cs a lone w ill c ause t he angiogenic 
response. S imultaneously, t he P DGF-BB w ill bi nd a nd a ctivate t he P DGFRs on  
SMCs, followed by an increased FGFR1 expression, which will be activated by FGF-
2 c ausing pr oliferation. F GFR1 a ctivation by F GF-2 bi nding w ill a lso c ause t he 
SMCs to  mig rate. As a r esult, v ascular r emodeling will o ccur. T he s ynergism 
between t he growth f actors i n t he t umors w ill lead t o c ross c ommunication of  t he 
cells leading to an elevated but mis-guided vessel growth in combination with a lack 
of proper SMC coverage and maturation, causing severe tumor growth and induction 
of m etastasizes. T his co uld b e an  i mportant f eature t o co nsider f or can cer t herapy, 
especially s ince i ncreased t umor v asculature a nd ab lated m ural c ells, ha ve be en 
shown t o be  a ssociated with m etastasis a nd poo r pr ognosis e ven i n c ancer pa tients 
[5].   
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4.2 PLGF PROMOTES NORMALIZED TUMOR VASCULATURE 
 
The V EGF-family c onsists of  t he di fferent m embers of  V EGF-A, -B, -C, D , a nd 
PlGF. T hese m embers h ave di fferent f unctions a nd c auses di fferent m orphological 
structures of  t he ve ssels. T he a ctions of  P lGF i s not  a s w ell de fined a s t he ot her 
members o f t he f amily. P lGF w hich bi nds e xclusively t o V EGFR1, m ight ha ve 
another f unction t han V EGF-A, which bi nds t o bot h V EGFR1 a nd R 2. V EGF-A 
mainly c auses t he pot ent a ngiogenic response v ia bi nding t o V EGFR2. H ere, w e 
would like to investigate the function of PlGF in association to tumor vascularization 
in mouse models, and further compare to human malignancies expressing endogenous 
PlGF. 
 
Comparing tumors overexpressing the angiogenic growth factors VEGF-A, P lGF-1, 
and PlGF-2, with the empty vector, we show that the VEGF-A fibrosarcoma (T241) 
tumors have an increased vessels density, the structure is irregular, torturous, full of 
vascular pl exus, a nd t he va scular b ranch poi nts a re m ore t han a  5 -fold hi gher 
compared with the vector. The vascular structure induced by both PlGF-1 and -2, are 
completely o f a d ifferent ch aracter; a n ormalized p henotype. T he v essels ar e l ong, 
straight and have few branch points. Another feature which differs in the PlGF in the 
induced v asculature i s t he s ize o f t he v essels. T he d iameter i s i ncreased 
approximately 3 -fold, g iving r ise t o a  l arge l umen. T he ve ssels of  t he ve ctor a nd 
VEGF-A groups have a smaller d iameter, due to an  abundance of microvessels and 
tip cells.  
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The pe ricytes are i mportant f or t he guidance of  pr oper va scular growth, s upport, 
stability, and prevention of leakage. We show the pericyte association of vessels to be 
sparse a nd onl y approximately ha lf of  t he ve ssels ha ve pe ricytes a ttached i n t he 
vector group. T he V EGF-A i nduced t umors ve ssels, ha ve e ven poo rer a mount of  
pericytes, and some are not attached to the vessels. In the PlGF tumors on the other 
hand, the pericytes cover most of  the vessels and a lmost the full entire endothelial-
surface. Then what about the functionality of these vessels? Through the injection of 
dextran, o f small molecular weight, we were ab le to evaluate the ex travasation ( the 
leakage) of  the vessels. The vector tumors proved to have highly permeable vessels 
leading were approximately half of the dextran being extravasated. In comparison, the 
VEGF-A overexpressing t umors ha d e ven m ore d extran l eaked ou t i nto t he 
extravascular s pace. T he P lGF i nduced ve ssels, with t he hi gh m ural c overage and 
normalized f eature, ha d m uch l ess va scular l eakage. F urther, w ill t he t umor 
vasculature be functional? Through the injection of a high molecular weight dextran, 
it was shown that almost 100% of the vessels in the PlGF tumors were perfused with 
blood. In contrast, onl y a  t hird of  t he V EGF-A i nduced ve ssels w ere pe rfused, 
proving the non-functionality of this tumor vasculature. 
 
To further evaluate if  the f indings of the P lGF vascular remodeling occurs in  o ther 
tumor t ypes, Lewis Lung C arcinoma ( LLC) cells ove rexpressing t he ve ry s ame 
growth factors as the fibrosarcoma cells were used. LLC is a more aggressive tumor 
type but also commonly used in research. The LLC tumor overexpressing PlGF-1 and 
-2 s howed t he s ame v ascular p attern as  f ibrosarcoma P lGF-1 a nd -2, w ith va scular 
normalization and high pericyte coverage. The vasculature in LLC-VEGF-A tumors 
also f ollowed t he same p attern as  f ibrosarcoma-VEGF-A, w ith a  hi gh num ber of  
branch poi nts a nd pe ricyte di ssociation. C omparing t he pe ricyte c overage with 
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fibrosarcoma, LLC ha d a bi t hi gher pe rcentile c overage, w hich h as t o d o w ith t he 
LLC tu mors its elf. It c an b e s peculated t hat o ther f actors, are ex pressed i n t hese 
tumors, which attract pericytes and lead to higher pericyte coverage. 
 
To an alyze f urther w hether t his v ascular n ormalization act ually o ccurs i n h uman 
tumors, we studied a human choriocarcinoma (JE-3) which intrinsically express high 
amounts of  homodimers of  P lGF, high amounts of he terodimers of  P lGF-VEGF-A, 
and low amounts of homodimers of VEGF-A. This tumor vasculature showed to be 
of normalized phenotype with a lmost 100% pericyte coverage corresponding to t he 
PlGF-induced ve ssels i n f ibrosarcoma and LLC. In comparison, w e us ed a  hum an 
squamous c ell c arcinoma ( A431), w hich expresses e xtremely l ow amounts of  
homodimers of PlGF and heterodimers of PlGF-VEGF-A, but high levels of VEGF-A 
homodimers.  Interestingly, the A431 tumor vasculature had extremely large vascular 
plexuses and only a  quarter of  the vasculature had pericyte coverage, s imilar to the 
VEGF-A pr oducing f ibrosarcoma and LLC t umors, a lthough t he A 431 va scular 
plexuses were of  l arger morphology.  The functionality of  t he v essels i n both J E-3 
and A431 remains to be studied.  
 
To evaluate the normalized vascular remodeling by PlGF, which transmits the signal 
through V EGFR1, w e i njected a  V EGFR1 ne utralizing a ntibody i nto the t umor 
bearing m ice. T o our  s urprise th e P lGF-induced v essels r emained i n a n ormalized 
manner with full pericyte coverage and few branch points. Interestingly, the diameter 
had decreased into the size found in vector tumors. Further, the tumor growth rate had 
not c hanged i n a ny o f t he PlGF- or ve ctor- tumor g roups. F urther, ve ctor t umors 
treated with the VEGFR2 neutralizing antibody, showed a reduced tumor growth rate 
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and a  nor malized va scular s tructure, w ith f ewer branch poi nts, but  w ith una ffected 
pericyte coverage and vessel diameter, compared to PBS treated tumors.  
 
Here we s how t hat t he m ain f unction of  P lGF i nduced v ascularization t hrough 
VEGFR1 is to dilate the vessel. In agreement to the observed phenotype in VEGFR1 
KO m ice, w hich di e dur ing t he e arly e mbryonic de velopment, du e to di sorganized 
and ove rgrown va sculature [62], our r esult i ndicate t hat VEGFR1 h ave a  ne gative 
regulatory role in angiogenesis. Further, the Flt-1 TK transgenic mice, which lack the 
intracellular dom ain of  V EGFR1 a nd onl y express t he s VEGFR1, a re a lso 
embryonically l ethal, but ex hibit a  normal neovascular phenotype [62]. In the mice 
carrying P lGF ove rexpressing t umors treated V EGFR1 ne utralizing a ntibodies t he 
normalized tumor vascular structure (although decreased lumen), could be due to the 
fact th at P lGF h eterodimerize w ith V EGF-A, and t hereby i nhibit t he V EGFR2 
induced angiogenesis via VEGF-A homodimers. The same vascular pattern was seen 
in anti-BEGFR1 t reated compared to PBS t reated vector tumors, which intrinsically 
express small amounts of mouse VEGF-A and PlGF. In conclusion, PlGF is causing 
vessel dilation and PlGF through dimerization with VEGF-A and thus neutralization 
of VEGF-A homodimer-induced VEGFR2 activation, induces normalization. 
 
4.3 PERICYTE REMOVAL MEDIATED THROUGH VEGFR1 IN THE 
RETINAL VASCULATURE 
 
Cancer- associated retinopathy (CAR) is a non-inflammatory damage of the retina of 
the eye; the research has been focused on t umor-induced autoimmune destruction of 
the retina with the focus of the photocell layers. In other types of retinopathy, such as 
diabetic r etinopathy ( DR) a nd r etinopathy of  prematurity ( ROP), a re e xtensive 
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research r egarding t he retinal va sculature and t he i mportant of  V EGF-A [ 48-51]. 
Here, we would like to investigate the retinal vessels, and the vascular changes due to 
tumor expressed angiogenic factors, and further the underlying mechanisms. 
 
To start, we found that the retinal distribution of VEGFR1 and VEGFR2 was found to 
be on di fferent c ell t ypes. T he retinal va sculature s urprisingly l acks V EGFR2 
expression, but rather expresses VEGFR1. The VEGFR2 expression was found on the 
nonvascular cells, the ganglion cells and photoreceptors, seen by the overlap staining 
of a nti-VEGFR2 a nd a  glial m arker.  T he V EGFR1, on t he ot her ha nd, w as w ell 
distributed on the retinal blood vessels, with were also covered by pericytes. Since the 
mural c ells, p ericytes a nd S MCs a re imp ortant f or th e s tability a nd pr evention of  
vascular leakage, and these cells were investigated for the VEGFR1 expression. First, 
to id entify th ese is olated p rimary c ells, th ey w ere s tained p ositively f or P DGFR-β, 
which i s know n t o be  expressed on bot h pe ricytes a nd S MCs [8]. The i solated 
pericytes ex pressed NG-2, a  pe ricyte m arker, a nd a  s mall s ubpopulation e xpressed 
alpha smooth muscle actin (αSMA), and the contrary; SMCs expressed αSMA and a 
subpopulation expressed NG-2. Both primary cells types were expressing VEGFR1, 
and further the pericytes and ECs also expressed the VEGFR1 mRNA confirmed by 
reverse-transcriptase PCR analysis. The signal transduction pathways induced in the 
pericytes after VEGF-A-stimulation, were confirmed to be the ERK-pathway and cell 
survival pathway through Akt. Erk activation could be inhibited by the anti-VEGFR1 
treatment. Taken together, here we have shown the direct activation of VEGF-A via 
VEGFR1 on pericytes in the retinal vasculature.   
 
VEGF-A binds both VEGFR1 and 2, and a known effect is to of disperse the pericyte 
and de crease co verage, as  s een i n t umors o verexpressing VEGF-A. If w e t hen 
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compare with P lGF which binds VEGFR1 a lone, which has b een proven to i nduce 
high p ericyte c overage i n t he t umor-vasculature, w ould t he retinal v asculature 
respond in the same pattern, in spite of the fact that tumor microvessels express both 
VEGFR1 and VEGFR2, and the retinal vasculature lack the VEGFR2 expression? In 
the i nvestigation, of  w hether onl y V EGF-A a ctivation of  t he V EGFR1 on r etinal 
vessels or if PlGF also induce the VEGFR1 induction of pericyte ablation; the micro-
pocket assay were used.  We placed small pellets containing VEGF-A or PlGF in the 
cornea a nd bot h V EGF-A a nd P lGF i nduced p ericyte a blation, and e ven i ncreased 
ablation a fter lo nger time  s timulation o f th e growth f actors. Further in  s ystemic 
delivery o f ad enoviral v ector expressing VEGF-A al so ablated t he p ericytes o f t he 
retina vasculature, compared to the empty vector.  
 
Pericytes are known to respond and migrate toward a chemo-gradient of PDGF-BB, 
via activation of  PDGFRβ, therefore we needed to compare the retinal vasculature of 
retinas f rom mic e tr eated w ith a  n eutralizing a ntibody a gainst P DGFRβ (anti-
PDGFRβ), and imatinib, the tyrosine kinase receptor inhibitor of PDGFRβ (STI571). 
After administration o f th ese tw o i nhibitors t here was a cl ear p ericyte ablation. 
Although after 25 d ays, t he ablation w as not  as hi gh c ompared t o t he V EGF-A 
administrated retinas.  
 
For more relevance of tumor induced retinopathy, retinas of tumor-bearing mice were 
examined. T wo di fferent t umor t ypes ( T241 and LLC) ov erexpressing V EGF-A, 
induced a pericyte loss in the retinal vasculature, cooperating the effects on the tumor 
vasculature seen in previous experiments. Further, the same ablation could be seen in 
the r etinal v asculature of P lGF-T241 be aring m ice. T hat P lGF ha ve t he s ame 
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induction of  pe ricyte l oss, l eads t o t he confirmation t hat V EGFR1 i nduces t he 
ablation process. 
 
Pericyte ablation would probably lead to decreased stability and functionality of the 
retinal vasculature. We, therefore, evaluated the retinal vascular l eakage by dextran 
injection into the tumor bearing mice. The VEGF-A-tumor mice hade large areas of 
vascular l eakage co mpared t o t he l ack o f l eakage i n t he r etinal ar eas o f t he w t- or 
vector-tumors mice. This indicates that the vasculatures with the ablated pericytes are 
less leaky, which is not healthy and can lead to tissue edema.  
 
The retinas of  mice with T241-VEGF-A tumors had increased pericyte coverage o f 
the r etinal v essels w hen tr eated w ith a nti-VEGFR1 a nd a nti-VEGF. T he an ti-
VEGFR2 t reatment h ad n one ef fect o f t he p ericyte coverage. T o v alidate t hese 
findings in a  model, where the expression levels of  angiogenic factors has not  been 
manipulated; a mouse model which spontaneous develops mammary adenocarcinoma 
was u sed. T he r etinas al so h ad i ncreased and r ecovered p ericyte as sociation o f t he 
vessels when t reated with an ti-VEGFR1. Further, no s uch loss could be  detected in 
the anti-VEGFR2 treated retinas.  
 
In c onclusion, w e ha ve f ound a  ne w m echanism of  r escuing th e imp aired r etinal 
vasculature i n C AR i n s everal d ifferent m ouse can cer m odels. T he d amaged 
vasculature, b y t he V EGF-A i nduced pe ricyte l oss; c ould be  i nhibited by s ystemic 
administration of anti-VEGFR1, but not anti-VEGFR2  antibodies.  
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4.4 ANTI-ANGIOGENIC DRUGS INCREASE SURVIVAL AGAINST 
CHEMOTHERAPY TOXICITY 
 
Chemotherapy is an efficiently used cancer treatment, although the severe side-effects 
can be lethal. One of the most severe side-effects is bone marrow (BM) suppression, 
which c ould c ause s evere anaemia. Anti-angiogenic d rugs ar e o ften administrated 
simultaneous with the chemotherapeutic agents. There is previously not much known 
of the mechanisms behind the benefits and of co-administrering anti-angiogenic drugs 
and chemotherapy. Here we show that tumor-VEGF-A induced BM suppression, can 
be inhibited by the anti-angiogenic drug. 
 
To assess the question whether the combination of the anti-angiogenic drug sunitinib 
and the chemotherapeutic drug carboplatin would in improve the survival compared 
to the carboplatin treatment alone, we used a B16-melanoma mouse model.  The mice 
treated with s unitinib a lone, ha d a f ull s urvival until t he e nd of  t he e xperiment, i n 
comparison to the control treated mice which had a 70% survival, and further as few 
as 20% of the carboplatin treated mice survived.   
When t he m ice w ere t reated w ith s unitinib f or 6 da ys t hen f ollowed b y t he 
administration of  bot h sunitinib a nd c arboplatin, t he s urvival i mproved t o 80% . 
Interestingly, primary tr eatment w ith sunitinib, followed b y c arboplatin tr eatment 
alone r esulted i n 100 % s urvival. T hese findings, di d not  a ccord w ith t he t umor 
growth, showing that the poor  prognosis of  carboplatin therapy i s not due to tumor 
size.  
 
Patients t reated w ith ch emotherapeutic d rugs o ften suffer fro m s evere s ide-effects 
including the lif e-threatening BM suppression [ 3]. P reviously, Xue et a l has shown 
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that VE GF-A-induced i mpaired m urine he matopoiesis c ould be  i mproved b y t he 
treatment w ith B evacizumab ( anti-VEGF-A) a nd a n a nti-VEGFR2 a ntibody, 
respectively [4]. Therefore we were interested in examining the BM of these mice. In 
comparison to the non -tumor bearing m ice, i n t hose w ith tumors, t he B M had a 
scattered appearance of the hematopoietic islet. As expected the melanoma mice had 
slightly decreased Red Blood Cell (RBC) counts, and surprisingly increased numbers 
of White B lood C ells ( WBC). C arboplatin s uppress th e BM in  p atients, a nd w hen 
carboplatin w ere u sed as a s ingle t reatment, t here w here l arge ar eas o f em pty 
extracellular spaces and the hematopoietic islands contained fewer cells compared to 
buffer treated BMs. When treating the melanoma mice with sunitinib alone, the BM 
where not suppressed, but rather contained more BM cells in comparison to the buffer 
treated mice. When pre-treating the mice with sunitinib, the carboplatin induced BM 
suppression was blocked, both in regard to the of hematopoietic is lets and numbe f  
circulation  RBCs and hemoglobin (HGB).  
Looking at the tumor vascularization of these mice, we found that sunitinib alone lead 
to decreased an giogenesis i n co mparison t o the b uffer t reated m ice. T he treatment 
with carboplatin alone showed the same amount of tumor vessels as the buffer treated 
mice. When sunitinib and carboplatin were used in combination the amount of tumor 
vessels was unc hanged when c ompared t o s unitinib a lone. Following c onsecutive 
treatment w ith sunitinib a nd c arboplatin, t he v ascularization w as i ncreased. This 
shows, t hat a fter t he s top of  s unitinib t reatment, t he pr ocess of a ngiogenesis w ill 
continue and that carboplatin have no anti-vascular effects. 
 
As mentioned above, VEGF-A can damage the BM. Can sunitinib treatment prevent 
this da mage?  T o i nvestigate t his, f ibrosarcoma e xpressing a n e mpty v ector or a  
VEGF-A-expressing v ector, w ere i njected and grown on m ice. T he s urvival of  t he 
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VEGF-A group w ere l ow, onl y 40% w ere s till a live a fter 18  da ys, w hereas every 
single m ouse i n t he ve ctor-group ha d s urvived. The f ast growing V EGF-A t umors 
caused s evere B M d amage. V ery f ew s mall h ematopoietic i slands w ere visible a nd 
the blood contained much less of RBCs and HGB, in comparison to the vector. Could 
sunitinib rescue the BM and perhaps even increase the survival? To investigate this, 
we started treating mice with sunitinib at the time the mice were about to become ill. 
This w ould more cl osely reflect t he t ime poi nt, when a  pa tient s eeks he lp f or their 
illness. Interestingly, the VEGF-A induced death could be delayed with several days 
due t o t he s unitinib a dministration. F urther, t his g roup h ad a r escued B M c ell 
population, and hematopoiesis. The vector-tumor baring mice treated with sunitinib 
shoved none such effect of  the BM. Here we showed that sunitinib can prevent the 
VEGF-A induced BM suppression. 
 
Since, V EGF-A s uppress t he B M, would the c ombination of s uch tumor w ith 
chemotherapy increase the BM suppression even more, even though these agents with 
high pr obability w ork t hrough di fferent, VE GF-unrelated mechanisms? One of  t he 
most common chemotherapies used is carboplatin, due to its efficiency. The liability, 
is the severe BM suppressing side-effects. The d ramatic result f rom the carboplatin 
treatment o f V EGF-A t umor be aring m ice, w as onl y 20% s urvival a fter 5 da ys of  
chemotherapy administration. We wondered if this low survival was only an effect of 
carboplatin, s pecifically, or  i f ot her c hemotherapeutic a gents would ha ve t he s ame 
synergistic effect. We tested CTX, which also causes BM suppression, although not 
as severe as that seen in patients treated with carboplatin. This combination of VEGF-
A expressing tumors treated with CTX, gave a 30% survival. Both chemotherapeutic 
agents induced decreased B M cells a nd e xtremely s mall h ematopoietic is lets w ith 
enormous areas of non-cellular space in the VEGF-A bearing mice. The blood counts 
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shoved decreased RBC and HGB in both groups. There is a synergistic effect of two 
different kind of chemotherapeutic drugs with VEGF-A, on BM suppression, leading 
to early death. 
 
The severe synergistic effects of the chemotherapy and VEGF-A expressing tumors, 
could perhaps be decreased with an anti-VEGF-A agent. If this agent is given before 
chemotherapy, would i t not  t hen g ive t he B M a  c hance t o r ecover, before t he 
chemotherapy-induced s uppression? When s unitinib w as a dministrated f or 5 da ys, 
followed by carboplatin, the mice exhibited an 80% survival rate. Sunitinib followed 
by a  c ombination of sunitinib and carboplatin l ed t o a 50 % survival r ate. Sunitinib 
followed b y buf fer or  a c ombination of  s unitinib a nd c arboplatin w ithout a ny pre-
treatment, g ave a ve ry poor survival of  10 % in both e xperimental s et-ups. 
Remarkably, t he BMs o f s unitinib f ollowed b y carboplatin a lone ha d as m any BM 
cells a s s ingle tr eatment o f s unitinib. T his c onsecutive treatment h ad a h ealthier 
phenotype of  t he B M, c ompared t o s unitinib f ollowed b y c ombination of  s unitinib 
and car boplatin. T he R BC an d H GB v alues were i ncreased i n al l c ases w here 
sunitinib ha d be en i n p re-treatment. T hese da ta pr oves t hat s unitinib r escues t he 
chemotherapeutic a gent i nduced B M s uppression, w hen administrated before t he 
agent.  
Further, s unitinib t reated t umors ha d l ess vascularization while the treatment was 
maintained but; when sunitinib was removed then the angiogenesis continued. When 
sunitinib w as a dministrated dur ing t he w hole experiment, w here c arboplatin w as 
added later on, the vascularization was normalized, but the BM was not. Thereby this 
kind of treatment caused a higher death amongst these mice.  
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To further evaluate if sunitinib can rescue chemotherapy induced BM suppression by 
another agent, we performed the same experiment with CTX instead of carboplatin. 
We f ound t hat pr e-treatment of  s unitinib di d i mprove t he s urvival, c ompared t o 
combination of both sunitinib and CTX simultaneously. The BM cell amounts were 
clearly increased in the sunitinib pre-treatment group. In conclusion, sunitinib given 
before the chemotherapy will serve as a protection toward the chemotherapy induced 
BM suppression. 
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5 CONCLUSION AND FUTURE PERSPECTIVES 
 
5.1 PAPER I: 
 
Here we studied the interplay between two angiogenic factors commonly expressed in 
advanced tumors. The vasculature is composed of both ECs and mural cells. The EC 
forms t he ve ssels a nd t he m ural c ells gives s tructural s upport but  a lso c ontrol t he 
blood flow within the vessel. Since ECs express the FGFR1 constantly, in presence of 
the ligand FGF-2 two actions will occur; receptor activation followed by expression 
of PDGFRs, and EC proliferation. When PDGF-BB is present, then the ECs start to 
migrate. In t he c ases w here t his i s i nduced b y r egulate ch emotactic s timuli, t he 
migration would occur in s trictly regulated manner, where one EC form a s o cal led 
tip cell, and proliferation of the stalk ECs will form a lumen. In tumors when FGF-2 
and PDGF-BB a re p resent everywhere; the E Cs f orm v essels w hich are instead 
irregular and full of vascular plexuses. This mechanism might be able to be inhibited 
by the mural cell-EC interactions, although mural cells too, respond to these growth 
factors. T he S MCs e xpress P DGFRs, w hich u pon P RGF-BB l igand b inding a re 
activated and causes FGFR1 expression. When the FGF-2 is bound to its receptor, it 
will cause the SMCs to  migrate. S ince the SMCs migrating away from the vessels, 
toward t he t umor c ells w hich a re pr oducing FGF-2, the ECs ar e exposed t o t he 
growth factors. Co-culture of SMCs and ECs will inhibit the EC proliferation, which 
otherwise w ill [108]. Thus i n t umors e xpressing bot h of  t hese f actors, v ascular 
remodeling and de stabilization will o ccur. T hese v ascular s tructures ar e highly 
permeable and migratory tumor cells can easily enter the blood stream, and spread to 
and colonize other tissues, and have thereby caused a metastasis. We found that 30% 
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of the mice had metastasis in the lungs, and further 40% of the lung tissues did carry 
the tumors cells. It can be speculated, that over time even the remaining mice might 
also develop metastasises. It has been shown, in patients that ablated mural cells in 
the tumor vasculature, is associated with increased metastasis and poorer prognosis of 
the cancer patient [14].   
 
We can look a t these f indings with two perspectives. 1)  W hen both PGDF-BB a nd 
FGF-2 a re e xpressed i n t umors, i t c ould l ead t o i nduced t umor g rowth, a nd 
metastasis. 2)  T he b eneficial ef fects o f p ro-angiogenesis. T he c ombination of  t hese 
two f actors could be  used a s a  ne w a pproach i n t he therapeutic pro-angiogenesis 
research field. In heart ischemic tissue, all single pro-angiogenic factors have failed, 
and not induced any new highly functional, arterial vessels. This has caused a h alter 
in the pro-angiogenic research. We have shown in an i schemic rat-hind l imb model 
that FGF-2 and PDGF induced long lasting and functional vessels [109]. Further, we 
showed i n a  pi g m yocardial i nfarction m odel t hat F GF-2 a nd P DGF-BB c ould 
improve the myocardial function, by establishment stable collateral networks, which 
induced improved blood flow [110]. Hopefully, this will lead to an increased interest 
in the pro-angiogenic research feild, and if this synergism of FGF and PDGF could be 
further i nvestigated. M aybe i t could be  us ed a s a treatment for p atients w ith 
myocardial infarcts in the future.  
Returning t o t he a nti-angiogensis aspect, f urther s tudies ne eds to be  pe rformed, t o 
evaluate an ti-angiogenic t herapeutic dr ugs. It w ould be  i nteresting t o t ry whether 
imatinib or  s unitinib w ould nor malize t he va sculature of  t hese t umors, or  j ust 
decrease t he ef fect t o a single-factor i nduced angiogenesis. S ince b oth d rugs t arget 
the PRDGFRs on both ECs and SMCs, it is most likely to result in full normalization, 
and thereby reduced tumor growth. Maybe in the future patients could be scanned for 
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both f actors a nd i t would m ost pr obably be a  marker f or poor er pr ognosis, a nd 
perhaps an indication of which treatment to use. 
 
5.2 PAPER II: 
 
We s tudied f ibrosarcoma ove rexpressing P lGF and s howed t hat t he t umor ha ve a  
normalized vasculature, with very few branches. In comparison the vector tumor had 
an i ncreased amount of  vascular b ranches, a nd f urther t he pot ent a ngiogenic f actor 
VEGF-A ha d fully i rregular a nd t orturous v essels. T he P lGF i nduced m icrovessels 
had enlarged lumens and the vessels had extensive pericyte coverage. This coverage 
is h ighly imp ortant for th e v ascular s tability, p ermeability and f unctionality. T hese 
vessels w ere f ully f unctional ha d ha d e xtremely l ow l eakage i n c omparison t o t he 
vector tumor, were about half of the vessels lacked perfusion.  
 
Interestingly, s tudying c horiocarcinoma, a  c ell lin e d erived f rom a  c linical tu mor 
sample an d which in trinsically e xpress high l evels of  PlGF, w e f ound t hat t he 
vascular s tructures r esembles t hose i n P lGF ex pressing fibrosarcoma. T he 
microvessels of choriocarcinoma had few branch points, high pericyte coverage, and 
a nor malized ph enotype. A s s hown i n t he f ibrosarcoma c ell l ine, t he normalized 
vessels w ere functional. W hat a lso i s s o i nteresting, i s t hat C horiocarcinoma ha s a 
very good prognosis and is highly sensitive to chemotherapy [111]. This is probably 
due to the highly functional tumor vessels, as the chemotherapeutic agents are thus 
better able to reach the tumor tissue. In the case of the chaotic tumor vessel structure, 
seen i n VEGF-A producing tumors, t he functionality o f t hese vessels a re ve ry l ow. 
That means that the therapeutic drugs might not even reach some areas of the tumor 
tissue. Taken t ogether w ith the f act that th ese VEGF-A-induced vessels ar e h ighly 
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leaky, causing high interstitial fluid pressure (IFP) in these kinds of tumors, it would 
make i t di fficult f or a ny ki nd of  e xchange f rom he althy t o t umor ve ssels [15]. A n 
example o f th is i s t he lacking a bility of  t umor ve ssels t o s upport s ufficient oxygen 
exchange, w hich m akes t he t umor t issue h ypoxic. A nti-angiogenic t herapy causes 
normalization, a nd t hat could arguable be t he c ause o f w hy anti-angiogenic d rugs 
show clinical benefits together with chemotherapy. S ince anti-angiogenic drugs l ike 
sunitinib, normalizes the vasculature, and PlGF do the same, therefore PlGF could be 
used a s a  bi omarker, f or w hen t he t umor w ould be  s ensitive f or c hemotherapy.  It 
would be very interesting to pay more attention to this. What would the outcome be 
if, w e t reated t hese f ibrosarcomas expressing t he e mpty ve ctor or  PlGF with 
chemotherapeutic agents? Sunitinib, had no be neficial effect on the PlGF expressing 
tumors, but  w ould t he t argeted r eceptor a ntibody ha ve s o? F urther, t he 
choriocarcinoma c ells a re a lso w orth s tudying m ore, s ince t hese hum an t umors a re 
sensitive for chemotherapy; there might be other important knowledge to be revealed 
regarding what makes some tumors sensitive and others not. 
 
5.3 PAPER III: 
 
Cancer-associated r etinopathy i s currently a non-treatable d isease, even t hough i t i s 
uncommon, and therefore it is important to find promising therapeutic targets. Since 
anti-VEGF-A treatment has not been reported, to be applied in the treatment of CAR, 
it w ould be  a  n ew approach. A lthough i t s hould be  a  t reatment t argeting V EGFR1 
which a re expressed o n t he va sculature a nd not V EGFR2, s ince V EGFR2 a re 
expressed on t he phot oreceptors. T he phot oreceptors w hich a lready are affected i n 
CAR and are therefore weakened in for the patient, these cannot sustain to be further 
attacked by some kind of treatment. Therefore the further research in this field has to 
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be co nducted w ith car e. T he ef fects o f V EGF-A bi nding t o t he V EGFR2 on t hese 
photocells ne ed f urther investigation. It w ould be i nteresting t o s tudy t he va scular 
effects of bevacizumab, t argeting VEGF-A, in CAR since it is  used in  o ther ocular 
diseases. A lthough t hen P lGF w ould not  be  a ffected, but  V EGFR2 on t he 
photoreceptors c ells would. T herefore i t w ould be  of  great i nterest t o f urther 
investigate the effects on retinal vasculature by targeting VEGFR1 directly.  
Our r esearch i s f ocused o n t he v asculature. The m alfunctioning r etinal vessels i n 
CAR a re i n ne ed of  e valuation, a nd he re w e ha ve f ound t hat these ve ssels do no t 
express V EGFR2, but  exclusively VEGFR1. F urther, t hese v essels a re i mpaired, 
lacking pr otecting pe ricyte c overage a nd a re l eaky. T his l eak can cause retinal 
hemorrhage a nd edema. T herefor f urther i nvestigations a re n eeded, t o evaluate if 
VEGFR1 could be targeted as a therapeutic approach.   
 
5.4 PAPER IV: 
 
Chemotherapy is one of the most efficient cancer treatments of certain tumor types. 
The d raw-back o f ch emotherapeutic d rugs, a re the s evere s ide-effects. H air l oss, 
nausea, ki dney cytotoxicity, bone  m arrow ( BM) s uppression, i s just a few o f t he 
many s ide-effects c aused b y ch emotherapeutic agents. T he BM s uppression, alone 
could l ead t o s evere a nd life-threatening anemia, he morrhage, and d ecreased bl ood 
clotting, decreased i mmune r esponse, which can cause d eath b y a s imple i nfection. 
Anti-angiogenic dr ugs are s imultaneously administrated w ith th e c hemotherapeutic 
agents. T here i s not  m uch know n of t he m echanisms behind t he be nefits of t his 
combination and here we show that tumor-VEGF-A-induced BM suppression, can be 
inhibited by the anti-angiogenic drug sunitinib. Further, the chemotherapeutic drugs 
induces BM suppression, and in combination with tumors releasing VEGF-A, there 
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will be  a  s ynergistic and m uch m ore s evere B M s uppression. T his i ncreased 
suppression, c auses therapy-induced mo rtality. That c ould b e tr anslated to  p atients 
with VEGF-A expressing tumors, as they would have much more severe and maybe 
even be lethal bone marrow toxicity when treated with chemotherapy. But for patients 
much more is needed to be investigated. Here, we show that if the anti-VEGF drug is 
given before th e chemotherapies, th e BM w ill be mo re n ormalized a nd th is w ill 
rescue the mice, and prevent the increased mortality induced by the chemotherapies. 
Sunitinib w hich is  a  mu lti-tyrosine ki nase i nhibitor i nduces t his r escue of t he BM 
cells, a nd i n pr evious publ ications w e ha ve s hown, t hat a nti-VEGFR2 would a lso 
prevent the VEGF-A induced BM damage. It needs to be further investigated whether 
other inhibitors, e.g. bevacizumab which is used in the clinical treatment of cancers, 
could cause the same rescue. Perhaps then these drugs could be used in other cancer 
types. Further, s ince w e he re s how t hat V EGF-A s hould be  s uppressed be fore t he 
chemotherapies, t o g ive t he B M a  ch ance t o r ecover, m aybe patients w ith known 
VEGF-A-expressing tumors or if we screen patients for tumor-VEGF-A expression, 
they could be t reated with the anti-VEGF-A drugs as  a p re-treatment. Even though, 
advanced tumors should be treated as aggressively, as soon as possible, maybe if the 
patient receives these “recovering” drugs first, the patient have a chance to be able to 
withstand th e s evere a nd s ometimes le thal s ide-effects i nduced by t he 
chemotherapies.  Further, when a patient have shown to have high VEGF-A values in 
the bl ood, pe rhaps i t s hould be  considered t o give ot her c hemotherapeutic dr ugs, 
which i s not  kno wn t o have highly BM su ppressing side-effects. Another poi nt o f 
view is that, anti-angiogenic drugs far from always have any beneficial effect on the 
tumor gr owth pe r s e. H ere we s howed i n t wo c ases, of  di fferent chemotherapeutic 
agents, that sunitinib ha d either no or  a b eneficial ( normalizing) e ffect on t he 
vasculature, but in both cases rescued the BM suppression. Although, much more is 
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to be investigated, here we propose a mechanism behind the beneficial effects of anti-
VEGF d rugs, and a  s chedule f or t heir de liver i n c ombination w ith c hemotherapy 
which maybe ought to be considered when designing clinical trial with such drugs in 
the futures.  
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